

September 25, 2025

CURRICULUM VITAE
STEPHANIE L. GRAFF, MD, FACP, FASCO

593 Eddy Street, George 3
Providence, Rhode Island 02903

401-444-5388

401-444-4184

SGraff1@brownhealth.org

Social Media: X (Twitter): @DrSGraff

BlueSky: @drsgraff.bsky.social

Instagram: DrSGraff

Co-Administrator, Hematology Oncology Women's Physician's Group, 2015-

Co-Administrator of @HemOncWomenDocs Twitter 2017-

EDUCATION

Undergraduate

University of Missouri-Kansas City, Liberal Arts,
Bachelor of Liberal Arts, 1998-2003

Medical School

University of Missouri-Kansas City School of
Medicine, 1998-2004, MD 2004

POSTGRADUATE TRAINING

Residency

University of Missouri – Kansas City School of
Medicine, 2411 Holmes Street, Kansas City,
Missouri 64108, Internal Medicine, 2004-2007

University of Missouri – Kansas City School of
Medicine, 2411 Holmes Street, Kansas City,
Missouri 64108, Internal Medicine Chief
Residency, 2007-2008

Fellowship

University of Kansas School of Medicine, 3901
Rainbow Boulevard, Kansas City, KS 66160,
Medical Oncology & Hematology Fellow, 2008-
2011 with Breast Oncology sub-fellowship 2010-
2011

Post-Graduate

American Society of Clinical Oncology Leadership
Development Program, 2318 Mill Road, Suite 800 |
Alexandria, VA 22314, June 2019-2021

POSTGRADUATE HONORS AND AWARDS

Girl Scout Gold Award, 1997

Gold Humanism Honor Society, The Arnold P. Gold Foundation, May 2007

Sirridge Award (for Outstanding Clinical Performance), University of Missouri Kansas City School
of Medicine Internal Medicine Residency Program, June 2007

Frist Humanitarian Award, HCA Midwest Health Research Medical Center, May 2017

Ingram's Top Doctors, Ingram's Magazine, Kansas City, MO, October 2017
 Fellow of the American College of Physicians (FACP), November 2018
 APEX Award for Publication Excellence, Social Media - Best Single Blog Post. Communications Concepts, 2019
 Women Leader in Oncology Nominee, Women Leaders in Oncology® 8th Annual Women Leaders in Oncology Reception, June 2021
 Benjamin L. Sapers, MD Memorial Award, American College of Physicians, Rhode Island Chapter, awarded to "an outstanding teacher, scholar with characteristic academic rigor and exchange, and evidence of empathy and humanism, superlative communication with patients and families", March 2022
 Excellence in Mentorship Award, Brown University Hematology Oncology Fellowship Program, Brown Alpert Medical School, June 2022
 Woman Disruptor of the Year, Healio® Disruptive Innovators 2022. Awarded to "a woman in the field of hematology/oncology who emerged as a leader and an example to younger of how a successful career can unfold. Awardee has had career of positive disruption and positive impact within specialty." June 2022
 APEX Award for Publication Excellence, Social Media – Single Blog Post. Communications Concepts, 2022
 GRASP Advocate Choice Award, in memory of Rhonda Mullins, San Antonio Breast Cancer Symposium 2023 for **Graff SL**, Freeman E, Roach M, Wilson R, Fairley R, Guallatte M, Stemland J, Chan B, Wochal P, Katz J, May-Slater S. Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making: Experiences and Perspectives of Patients, Caregivers, and Clinicians
 Fellow of the American Society of Clinical Oncology (FASCO), February 2024
 Master of Arts *ad eundem*, Brown University, May 2024
 American Society of Clinical Oncology 2023 Advocacy Champion, Speaker's Circle, April 2024
 LARVOL 2024 Top 100 Oncologists on X (#70) and Top Oncologists on X: Breast Cancer (#7)
 E. Grey Diamond Take Wing Award 2025, University of Missouri-Kansas City School of Medicine, The school's "highest annual honor awarded to a graduate who has demonstrated excellence in chosen field and exceeded the expectations of peers in the practice of medicine, academic medicine or research. Personal achievements and community or public service are also considered for the award." May 2025

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Medical License, State of Missouri, #2006006489, 2004 (Not active)
 Medical License, State of Kansas, #04-32923, 2008 (Not active)
 2018 American Board of Internal Medicine, Diplomate in Hematology, 2011;
 Maintenance of Certification in good standing, 2023
 American Board of Internal Medicine, Diplomate in Medical Oncology, 2011;
 Maintenance of Certification in good standing, 2023
 American Board of Internal Medicine, Diplomate in Internal Medicine, 2007; 10-year Recertification 2017
 Medical License, State of Rhode Island, #17458, 2021-

ACADEMIC APPOINTMENTS

Assistant Professor, Department of Medicine, Warren Alpert Medical School, Brown University, June 2021-July 2023

Director of Breast Oncology, Brown University Health Cancer Institute, Providence, Rhode Island, 2021-
 Arts & Medicine Track, Internal Medicine and Medicine-Pediatrics Residency Program, Brown University, Faculty & Mentor, 2022-
 Mentor, Doctoring Mentor Program, Warren Alpert Medical School, Brown University, 2022-2024
 Associate Professor, Department of Medicine, Warren Alpert Medical School, Brown University, July 2023-
 Associate Director, Global Oncology and Policy, Legorreta Cancer Center at Brown University, July 2025-

HOSPITAL APPOINTMENTS

Attending Physician, Department of Internal Medicine, St. Luke's Hospital, Kansas City, Missouri 2007-2008
 Breast Oncologist, Sarah Cannon Cancer Institutes (Midwest Cancer Care), HCA Midwest, Kansas City metropolitan area, Kansas and Missouri, 2011- 2021.
 National Breast Lead, Clinical Programs, Sarah Cannon Cancer Institute Network, Nashville, Tennessee, 2016- 2021.
 Director, Breast Program, Sarah Cannon Cancer Institute at HCA Midwest Health, Kansas City, Missouri. 2016- 2021.
 Associate Director, Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, Tennessee, 2017- 2021
 Director, Clinical Research Program, Sarah Cannon Cancer Institute at HCA Midwest Health, Kansas City, Missouri. 2020-2021
 Director of Breast Oncology, Brown University Health Cancer Institute, Providence, Rhode Island, 2021-

OTHER APPOINTMENTS

Editorial Positions

Associate Editor

Cancer Medicine, Breast & Gynecologic Oncology, 2022-2023

Section Editor

Missouri Medicine, Hematology & Medical Oncology, 2019- 2021

Editorial Board

Oncology Times, Chair, 2023-

Journal of Clinical Oncology, Art of Oncology, 2023-2025

Healio Women in Medicine Board, 2021-

American Journal of Clinical Oncology, 2021 -

Ad hoc Reviewer:

Journal of Clinical Oncology, 2018-

Journal of Oncology Practice, 2018-

Journal of the National Cancer Institute, 2020-

Breast Cancer Research and Treatment, 2021-

Nature Medicine, 2022-

"ASCO Reading Room" for *MedPageToday*, 2021 –

Cancer, 2022-

New England Journal of Medicine, 2023-

The BMJ, 2023-
Journal of the National Cancer Institute, 2024-
ESMO Open, 2024-

HOSPITAL COMMITTEES

Performance Improvement Committee, Research Medical Center, 2012 - 2014
 Oncology Evidence Based Order Set Committee, HCA Healthcare, Nashville 2011-2012
 Breast Program Leadership Committee, Chair, Centerpoint Medical Center, 2012- 2012
 Institutional Review Board, HCA Midwest Health System, 2012 - 2013
 Commission on Cancer Committee, Research Medical Center, Kansas City, 2012 - 2015
 Commission on Cancer Committee, Vice-Chair: HCA Midwest Health Division, 2016 - 2021
 National Accreditation Program for Breast Centers (NAPBC) Breast Program Leadership Committee Chair, Research Medical Center; 2011-2021
 National Accreditation Program for Breast Centers (NAPBC) Breast Program Leadership Committee member, Menorah Medical Center, 2013-2021
 Kansas City Cancer Governance Board, HCA Midwest Health System/Sarah Cannon Cancer Institute, 2013-present
 Breast Workgroup, HCA Midwest Health System/Sarah Cannon Cancer Institute, Chair 2013-present
 Health Outcomes Research Steering Committee, Sarah Cannon Research Institute, Member, 2017-2021
 Breast Steering Committee, Brown University Health Cancer Institute, Member, June 2021-
 Breast & Pelvic Malignancies Academic Working Group, Brown University Health Cancer Institute, June 2021 -
 Scientific Review & Monitoring Committee, Brown University Health Office of Cancer Research, Brown University Health Cancer Institute, Member, July 2021- July 2022 and May 2025 - April 2028; Expedited Reviewer, March 2022 – present;
 Brown University Health Cancer Institute Executive Committee, July 2021-
 Search Committee, Breast & GYN Oncologist search, Chair, Department of Medicine, Division of Hematology & Medical Oncology, July 2021- January 2022
 Brown University Health Cancer Institute Multidisciplinary Tumor Board, Chair, January 2022-
 Brown University Health Cancer Institute Breast Cancer Strategic Retreat, Lead, April 2022
 Brown University Health Cancer Institute Operations Council, October 2022 -
 2023 Day of Giving Executive Committee, Rhode Island Hospital, November 2022 – March 2023
 Search Committee, Breast & GYN Oncologist search, Department of Medicine, Division of Hematology & Medical Oncology, Chair, November 2023 – August 2024
 Search Committee, Assistant or Associate Professor of Biostatistics search, Department of Biostatistics in collaboration with Legoretta Cancer Center, Member, August 2024 –
 Search Committee, Section Chief of Breast Surgery search, Department of Surgery, Member, February 2025 -

UNIVERSITY COMMITTEES

Evaluations and Competency Committee, University of Missouri-Kansas City Internal Medicine Residency, 2006 - 2008
 Internal Medicine Residency Committee, University of Missouri-Kansas City Internal Medicine Residency, 2007 - 2008

Leadership Committee, University of Missouri-Kansas City Internal Medicine Residency, 2006 - 2008

Circulating Tumor Cells Working Group, University of Kansas Cancer Center, 2009 – 2010

Co-Lead, Breast Cancer Translational Research Disease Group (TRDG), Legorreta Cancer Center at Brown University, June 2021-April 2025

Search Committee, Breast & GYN Oncologist search, Chair, Brown University, July 2021- January 2022

Joint Program in Cancer Biology Search Committee, Member, Brown University, July 2021- Breast & GYN Malignancy Journal Club Co-Chair, Twitter Spaces, Legorreta Cancer Center at Brown University, August 2021- June 2023

Co-Chair, Brown University Oncology Cooperative Group (BrUOG) Breast Committee, November 2021-

Center for Interdisciplinary Translational Cancer Research Grant Review Committee, Brown University, January 2022

Search Committee, Immuno-Oncologist, Brown BioMed Department of Medicine, Diversity Representative, July 2022-

Legorreta Cancer Center Data Science Working Group, Brown University, December 2022 – Legorreta Cancer Center Cancer Therapeutics Program, Brown University, March 2022 – Medical Faculty Executive Committee, Brown University, 2023 –

Institutional Review Board Collaborative Research Engagement Workgroup (CREW), January 2024 –

Legorreta Cancer Center Leadership Advisory Group, Brown University, January 2024-

Legorreta Cancer Center American Cancer Society Institutional Review Grant Committee, February 2024, December 2024

Co-Director, Breast Cancer Translational Research Disease Group (TRDG), Legorreta Cancer Center at Brown University, April 2024-

Alcohol & Breast Cancer Work Group, Center for Alcohol and Addiction Studies (CAAS), School of Public Health, Brown University, November 2024-

Brown University Community Council (BUCC) July 2025 - June 2026, Medical Faculty Representative

NATIONAL COMMITTEES

Regional Steering Committee, Americas Region MonarchE Clinical Trial, Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) NCT03155997, Eli-Lilly, July 2018-2021

Collaboration for Outcomes using Social Media in Oncology (COSMO), June 2021-

SWOG Community Chair, “STOP CIPN: Randomized Trial of Limb CryocompreSsion versus ConTinuuous COMpression versus Low Cyclic Compression for the Prevention of Taxane InduCed PerIPheral Neuropathy (SWOG-S2205), NCT05642611, Funded by National Cancer Institute US NIH Grant UG1CA189974, March 2022-

The American Cancer Society National Breast Cancer Roundtable (ACS NBCRT), American Society of Clinical Oncology Representative, Risk Reduction, Screening, and Early Detection Priority Workgroup, March 2023-April 2024; Steering Committee, April 2024 -

INTERNATIONAL COMMITTEES

Global Manuscript Committee, Evaluation of Lasofoxifene versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With An ESR1 Mutation (ELAINE-1), NCT03781063, Sermonix Pharmaceuticals, July 2022-

Global Steering Committee, postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy, I3Y-MC-JPEF, NCT05169567, December 2021 –

Translational Science Steering Committee, MonarchE Clinical Trial, Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) NCT03155997, Eli-Lilly, September 2022-

Global Steering Committee, A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Durvalumab compared with Pembrolizumab in combination with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel/Gemcitabine+Carboplatin) in Patients with PDL1 positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05, NCT06103864), Astra-Zeneca, January 2023-

Co-Chair, Global Steering Committee, A phase IIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2– early breast cancer (Adjuvant WIDER, NCT05827081), Novartis, January 2023-

Abemaciclib and Imlunestrant Metastatic Breast Cancer Translational Steering Committee, Lilly, September 2023-

MEMBERSHIP IN SOCIETIES

American Society of Clinical Oncology (ASCO), 2009-
 ASCO University™ Fellows Advisory Group: 2009 – 2011
 Women in Oncology Strategic Planning Workgroup, 2017; ASCO
 Women In Oncology Working Group, 2020-2022
 ASCO Clinical Practice Guideline Implementation Network, Member, December 2017-
 ASCO Professional Development Committee, 2018- 2019; Women in Oncology
 subcommittee, 2018- 2019.
 ASCO Research Community Forum, 2018- 2021; Site Qualifications Working Group,
 2018- 2021
 ASCO Annual Meeting Women's Networking Center Mentor, 2019-
 ASCO Annual Meeting Women's Networking Center Planning Committee, 2020
 ASCO Advantage, Course Director
 “Cancer Basics for People With Cancer, Survivors, and the Public,” in partnership
 with Cancer.Net Alexandria VA, November 2019
 “Breast Cancer”: April 2020, Virtual; February 2021, Virtual; January 2023,
 Alexandria VA; October 2024 Dallas TX; January 2025 Baltimore MD
 “Breast & Lung Cancer”, Alexandria VA, August 2021
 ASCO Quality of Care Council, 2020- 2021
 ASCO Joint Certifications Committee, 2021-2023
 ASCO Advocacy Summit, Volunteer: May 2023, April 2024 (ASCO Advocacy
 Champion—Speaker's Circle), April 2025 (ASCO Advocacy
 Champion—Speaker's Circle)
 ASCO Expert Answers, 2023. *Developed Course Content and Recorded CME Module on*
“How do I treat refractory metastatic HR+/HER2- breast cancer”
 American Cancer Society National Breast Cancer Roundtable, ASCO Representative,
 Risk Reduction Workgroup Member, 2023-2024

ASCO Patient-Clinician Communication Guideline Consensus Panel, May 2023 –
 ASCO Drug Shortages Working Group and Breast Cancer Drug Shortages Working
 Group: Carboplatin/Cisplatin, May 2023 – July 2023
 Conquer Cancer Foundation & MaxMara American Society of Clinical Oncology
 Annual Meeting 2024 Fundraiser Co-Host, May 2024
 American Society of Clinical Oncology International Development and Education Award
 (IDEA) Program Mentor, 2024 -
 ASCO Annual Meeting Education Program Committee—Breast Cancer Track, June 2025-
 June 2028
 American College of Physicians (ACP), 2017-
 Rhode Island American College of Physicians 2023 Annual Meeting Planning
 Committee, 2022-
 American Association for Cancer Research (AACR), 2017-
 AACR, University of Texas Health San Antonio MD Anderson, San Antonio Breast Cancer
 Symposium Communications Team “San Antonio Breast Cancer Symposium 2023
 Social Media Supporter,” December 2023
 Association of Clinical Research Professionals (ACRP), 2020-
 European Society of Medical Oncology (ESMO), 2021-
 SWOG Cancer Research Network, October 2021-
 SWOG Digital Engagement Committee, October 2021 – May 2025
 Principal Investigator, Brown University Health Cancer Institute – Organizational Lead
 Principal Investigator, April 2022-
 Breast Committee, April 2022-
 SWOG Study Co-Chair, “Phase 3 Trial of Sequencing Antibody Drug Conjugates
 (ADCs) and OptimizinG Outcomes in HER2-Low Advanced/MEtastatic
 Breast Cancer (SAGE; SWOG-S2413), December 2022-November 2023,
 Non-Funded by NCI Breast Cancer Steering Committee (BCSC)
 Breast Committee Retreat, Fall 2023 SWOG Meeting, Chicago IL
 Early Drug Development and Rare Cancers Committee, April 2022-
 Liaison Early Drug Development and Rare Cancers Committee to the Breast
 Committee, April 2022-
 Alliance for Clinical Trials in Oncology, October 2021-
 The Alliance for Clinical Trials in Oncology Breast Cancer Committee, October 2021-
 National Consortium of Breast Centers, 2021-
 Primary Contact, Institutional Member, 2022-
 Clinical Track Committee, 2022- present; Chair, 2025-
 High-Risk Workshop Sub-Committee, 2022- present; Chair, 2023 -
 Multinational Association of Supportive Care in Cancer, 2023-
 Oncodermatology Study Group, 2023-
 Mucositis Study Group, 2023-
 Neurologic Complications Study Group, 2023-
 Rhode Island Medical Women’s Association, Member, 2024-
 European Society of Breast Cancer Specialists (EUSOMA) Multi-disiplinary Meeting Optimization
 Working Group, November 2024-

OTHER KEY APPOINTMENTS

Gilda’s Club Professional Resource Council: Gilda’s Club Kansas City, 2011- 2021

The Research Foundation, 2012-2021
 Research Foundation Board, member, 2019-2021,
 Research Foundation Board Finance subcommittee, 2019- 2021
 Research Foundation Bixby Symposium Director, 2020
 Chair, Research Foundation Cancer Symposium, 2013
 Research Foundation, Candlelight Ball Steering Committee, 2012- 2012
 Male Breast Cancer Coalition, Volunteer, 2017-
 American Cancer Society, 2018-
 American Cancer Society, New England/Rhode Island Leadership Council, August 2021-
 April 2024
 American Cancer Society, Kansas/Kansas City Area Board, Chair 2020-2021, Vice Chair
 November 2019-2020, Board Member April 2018-May 2021
 American Cancer Society National Breast Cancer Roundtable, 2023-
 ASCO Representative, Risk Reduction, Screening, and Early Detection Priority
 Workgroup Member, 2023-2024
 Steering Committee, 2024 - 2026
 Medical Advisor, Dr. Susan Love Foundation for Breast Cancer Research, September 2020-
 May 2024
 11th International Symposium on the Human Breast Planning Committee, June 2022-
 February 2023
 Grant Review Committee, \$20,000 Sharon D. Lund Foundation Grant
 Grant Review Committee, \$75,000 Gilead Oncology Foundation Grant for Triple
 Negative Breast Cancer In Black Women
 Breast Cancer in Young BRCA Carriers (BRCA BCY) Collaboration (Institute Jules Bordet,
 NCT02308085), Investigator, June 2022—
 National Fellows Forum—Breast Cancer, San Antonio Breast Cancer Symposium with OncLive,
 Chair Aug-Dec 2023, Chair Aug-Dec 2024, Faculty Aug-Dec 2025
 Study Medical Lead, Clinical Meaningfulness in Metastatic Breast Cancer, in partnership
 with PRECISIONheor and Gilead Oncology, May 2023-
 Caris Precision Oncology Alliance,
 Healthcare Disparities Council, June 2021-
 Breast Disease Group, June 2021- , Chair-Elect June 2021-22, Chair June 2022-
 June 2024
 St. Gallen's Breast Cancer Conference Social Media Scientific Editor, 2023; Social Media
 Ambassador, 2024
 Rhode Island American Society of Clinical Oncology State Affiliate (RIOS) Charter Initiative
 Executive Leadership Co-Chair, May 2023 – September 2024; Past-President September
 2024- August 2025
 Medical and Scientific Advisory Council, Male Breast Cancer Global Alliance, January 2024 –
 Worldwide Innovative Network (WIN), Co-Moderator, Breast Cancer Molecular Tumor Board,
 January 2024—
 Dempsey Center for Quality Cancer Care, Board of Directors, February 2024 -
 Duffy Null phenotype ANC Dose Modification Parameters Working Group, Dana Farber Cancer
 Institute, Breast Cancer Member, February 2024-
 SAFE-CAP Steering Committee, SAFE-CAP: A Phase II Trial to Improve Safety of Capivasertib
 for HR+/HER2- Metastatic Breast Cancer, Yale Cancer Center, April 2024-

FUNDED PROJECTS

1. Racial Disparities in Triple Negative Breast Cancer: Syngeneic mice models, \$100,000 Laboratory Research Project. (Funder: Grace Hortense Greenley Trust Grant, directed by The Research Foundation in memory of Eva Lee Caldwell), Co-Investigator Dr. Suman Kambhampati. Funded laboratory work at KC Veterans Affairs hospital looking at racial disparities in syngeneic mice models with triple negative breast cancer in partnership with Banerjee S, Banerjee SK. 11/2017- 2019
2. Prevention of datopotamab deruxtecan (TROP-2 directed ADC) Stomatitis in patients with HER2-negative metastatic breast cancer using Dexamethasone cryotherapy Mouthwash: a single-arm, phase 2 trial (TROPION-DM), Brown University Oncology Cooperative Group Trial # 431; \$1,200,000 Investigator initiated trial (Funder: Daiichi Sankyo) Principal Investigator. Primary Objective: Reduce incidence of all grade stomatitis; 07/2023 - Completion of enrollment.

PUBLICATIONS LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Gupta V, Haque I, Chakraborty J, **Graff SL**, Banerjee S, Banerjee SK. Racial disparity in breast cancer: can it be mattered for prognosis and therapy. J Cell Commun Signal. 2018 Mar;12(1):119-132. doi: 10.1007/s12079-017-0416-4. Epub 2017 Nov 29. PMID: 29188479; PMCID: PMC5842180.
2. Ghosh A, Sarkar S, Banerjee S, Behbod F, Tawfik O, McGregor D, **Graff SL**, Banerjee SK. MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis. PLoS One. 2018 May 29;13(5):e0198143. doi: 10.1371/journal.pone.0198143. PMID: 29813119; PMCID: PMC5973560.
3. Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, **Graff SL**, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22. PMID: 29787356.
4. **Graff SL**, Close J, Cole S, Matt-Amaral L, Beg R, Markham MJ. Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians. J Oncol Pract. 2018 Dec;14(12):e758-e769. doi: 10.1200/JOP.18.00448. PMID: 30537459.
5. Duma N, Durani U, Woods CB, Kankeu Fonkoua LA, Cook JM, Wee C, Fuentes HE, Gonzalez-Velez M, Murphy MC, Jain S, Marshall AL, **Graff SL**, Knoll MA. Evaluating Unconscious Bias: Speaker Introductions at an International Oncology Conference. J Clin Oncol. 2019 Dec 20;37(36):3538-3545. doi: 10.1200/JCO.19.01608. Epub 2019 Oct 11. PMID: 31603705
6. Woitowich NC, **Graff SL**, Swaroop M, Jain S. Gender-Specific Conferences and Symposia: A Putative Support Structure for Female Physicians. J Womens Health (Larchmt). 2020 Aug;29(8):1136-1141. doi: 10.1089/jwh.2019.7859. Epub 2019 Nov 7. PMID: 31697577.
7. **Graff SL**, Holder JM, Sears LE, Kurbegov D. Increase in Genetic Counseling and Testing Referrals After Breast Cancer Pathway Implementation. JCO Oncol Pract. 2020 Dec;16(12):e1481-e1488. doi: 10.1200/JOP.19.00552. Epub 2020 Jul 10. PMID:

32650693.

8. Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, Eisen A, Freedman RA, Gopalakrishnan R, **Graff SL**, Hassett MJ, King TA, Lyman GH, Maupin GR, Nunes R, Perkins CL, Telli ML, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. *J Clin Oncol*. 2021 Feb 20;39(6):685-693. doi: 10.1200/JCO.20.02510. Epub 2020 Oct 20. PMID: 33079579.
9. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; **monarchE Committee Members and Investigators**. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol*. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. PMID: 32954927; PMCID: PMC7768339.
MonarchE Regional Steering Committee Members: Abuin GG, Lim E, Santi P, Hegg R, Liao N, Christiansen B, Eigeliene N, Martin-Babau J, Ettl J, Mavroudis D, Chiu J, Lam PF, Boer K, Agarwal A, Nagarkar R, Paluch-Shimon S, Moscetti L, Sagara Y, Kim SB, Maciel MM, Tjan-Heijnen V, Broom R, Dolnoslaskie AL, Schenker M, Volkov N, Yap YS, Coccia-Portugal M, García Sáenz JA, Andersson A, Chao TY, Gokmen E, Harputluoglu H, Berzoy O, Patt D, McArthur H, Chew H, Chalasani P, Kaufman P, **Graff S**.
10. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Lorient Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; **KEYNOTE-361 Investigators**. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. PMID: 34051178.
KEYNOTE-361 Investigators: Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, David Hugo Flores, Agustin Falco, Matias Molina, Filip Van Aelst, Christof Vulsteke, Briec Sautois, Jean-Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sergio J Azevedo, Gisele Marinho, Joao Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, Andre Poisl Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, MarieVanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, Jose Luis Leal, Francisco Francisco, Carolina Ibanez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Flechon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross-Goupil, Stephane Culine, Yohann Lorient, Gwenaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David Pfister, Carsten Ohlman, Michael Stoeckle, Manfred Wirth, Anja Lorch, Guenter Niegisch, Peter J Goebell, Martin Boegemann, Axel Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian Thomas, Thomas Hoefner, Andras Telekes, Judit Erzsebet Kosa, Janos Revesz, Gyorgy Bodoky, Tibor Csoszi, Andras Csejtei, Lajos Geczi, Agnes Ruzsa, Zsuzsanna Kolonics, Jozsef Erfan, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Keizman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger, Keren Rouvinov, David Sarid, Satoshi Fukasawa, Gaku Arai, Akito Yamaguchi, Akira Yokomizo, Tatsuya Takayama, Hidefumi Kinoshita, Eiji Kikuchi, Ryuichi Mizuno, Yasuhisa Fujii, Naoto Sassa, Yoshihisa Matsukawa, Kiyohide Fujimoto, Nobuaki

- Matsubara, Toshiki Tanikawa, Yoshihiko Tomita, Kazuo Nishimura, Masao Tsujihata, Masafumi Oyama, Naoya Masumori, Hiroomi Kanayama, Toshimi Takano, Yuji Miura, Jun Miyazaki, Akira Joraku, Tomokazu Kimura, Yoshiaki Yamamoto, Kazuki Kobayashi, Ronald De Wit, Maureen Aarts, Winald Gerritsen, Maartje Los, Laurens Beerepoot, Adel Izmailov, Sergey Igorevich Gorelov, Boris Yakovlevich Alekseev, Andrey Semenov, Vladimir Anatolyevich Kostorov, Sergey M Alekseev, Alexander Zyryanov, Vasilii Nikolaevich Oschepkov, Vladimir Aleksandrovich Shidin, Vladimir Ivanovich Vladimirov, Rustem Airatovich Gafanov, Petr Alexandrovich Karlov, David Brian Anderson, Lucinda Shepherd, Graham Lawrence Cohen, Bernardo Louis Rapoport, Paul Ruff, Nari Lee, Woo Kyun Bae, Hyo Jin Lee, Urbano Anido Herranz, Alejo Rodriguez-Vida, Rafael Morales Barrera, Enrique Grande, Teresa Alonso Gordo, Josep Guma Padro, Daniel Castellano Gauna, Jose Angel Arranz, Jose Munoz Langa, Regina Girones Sarrio, Alvaro Montesa Pino, Maria Jose Juan Fita, Yu-Li Su, Yung-Chang Lin, Wen-Pin Su, Ying-Chun Shen, Yen-Hwa Chang, Yi-Hsiu Huang, Virote Sriuranpong, Phichai Chansriwong, Vichien Srimuninnimit, Pongwut Danchaivijitr, Huseyin Abali, Sinan Yavuz, Ozgur Ozyilkan, Mehmet Ali Nahit Sendur, Meltem Ekenel, Mustafa Ozguroglu, Cagatay Arslan, Seyda Gunduz, Mustafa Ozdogan, Alison Birtle, Thomas Powles, Robert Huddart, Maria de Santis, Anjali Zarkar, Linda Evans, Syed Hussain, Christopher DiSimone, Antonio F Muina, Peter Schlegel, Haresh S Jhangiani, Michael Harrison, Dennis E Slater, David Wright, Ivor J Percent, Jianqing Lin, Clara Hwang, Ronac Mamtani, Sumati Gupta, Madhuri Bajaj, Robert Galamaga, John Eklund, James Wallace, Mikhail Shtivelband, Jason Jung-Gon Suh, Nafisa Burhani, Matthew Eadens, Krishna Gunturu, Earle Burgess, John Wong, Arvind Chaudhry, Peter Van Veldhuizen, **Stephanie Graff**, Christian A Thomas, Ian D Schnadig, Benedito Carneiro, Maha Hussain, Alicia Morgans, John T Fitzharris, Ira A Oliff, Jacqueline Vuky, Ralph Hauke, Ari Baron, Monika Joshi, Britt H Bolemon, Peter Jiang, Anthony E Mega, Maurice Markus, Nicklas Pfanzelter, William Eyre Lawler, Patrick Wayne Cobb, Jay G Courtright, Sharad Jain, Gurjyot Doshi, Vijay K Gunuganti, Oliver Alton Sartor, Scott W Cole, Hani Babiker, Edward M Uchio, Alexandra Drakaki, Heather D Mannuel, Ajjai Alva, Elizabeth Guancial, Chunkit Fung, Anthony Charles, Robert J Amato, Yull Arriaga, Isaac Bowman, Steven Ades, Robert Dreicer, Evan Yu, David I Quinn, Mark Fleming,
11. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; **ASCENT Clinical Trial Investigators**. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med*. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206.
- ASCENT Clinical Trial Investigators:** Foluso Ademuyiwa, Philippe Aftimos, Anne Armstrong, Aditya Bardia, Frédéric Bigot, Adam Brufsky, Lourdes Calvo, Martínez, Lisa A Carey, Eva Ciruelos Gil, Alison Conlin, Javier Cortés, Florence Dalenc, Brooke Daniel, Michael Danso, Jorge Darcourt, Sami Diab, Jennifer Diamond, Véronique Diéras, Anne Favret, Mariía Fernáandez Abad, Cristiano Ferrario, Nelly Firmin, Christel Fontaine, Jean-Sebastien Frenel, Luca Gianni, **Stephanie Graff**, Erika Hamilton, Eric Harris, Lowell Hart, Susanna Hegewisch-, Becker Becker, Stéphanie Henry, Christie Hilton, Sara A Hurvitz, Sharad Jain, Kevin Kalinsky, Pinelopi Kechagioglou, Leonard Klein, Roberto Leon-Ferre, Florence Lerebours, Sibylle Loibl, Delphine Loirat, Rafael López, Filipa Lynce, Zulfiqar Malik, Laura Mansi, María Martínez García, Ingrid Mayer, Michael Meshad, Judith Meza-Junco, Rebecca Moroosse, Rita Nanda, Petros Nikolinakos, Joyce O'Shaughnessy, Mafalda

- Oliveira, Coral Omene, Felicity Paterson, Alejandra Perez, José Manuel Perez Garcia, Martine Piccart, Kevin Punie, Daniel Rayson, Sabela Recalde, Donald Richards, Paul Richards, Hope Rugo, Manuel Ruiz-Borrego, Mahasti Saghatchian, Sagar R Sardesai, Peter Schmid, Lowell Schnipper, Lee Schwartzberg, Priyanka Sharma, Amna Sheri, Saiqa Spensley, Christopher Stokoe, Jun Sun, Karen Tedesco, Sara M Tolaney, Tiffany Traina, Olivier Tredan, Michaela Tsai, Linda Vahdat, Tanya Wahl, Grace Wang, Robert Weaver, Rudolf Weide, Robyn Young, Amelia Zelnak
12. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordo T, Merchan JR, Winkvist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutkus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; **CLEAR Trial Investigators**. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med*. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. PMID: 33616314.
- CLEAR Trial Investigators:** Robert Motzer, Toni Choueiri, Thomas Hutson, Luke Nordquist, Johanna Chock Bendell, Jamie Merchan, Saby George, Sandy Srinivas, Ulka N Vaishampayan, Elisabeth Heath, Brendan Curti, Andrew Pippas, Subramanya S Rao, Harry Drabkin, Theodore Gourdin, Mehmood H Hashmi, Jason Jung-Gon Suh, Nafisa D Burhani, Ana M Molina, Alan Koletsky, Robert S Alter, Carlos Alemany, Benjamin A Gartrell, Mike Cusnir, Harsha Vyas, Peter Van Veldhuizen, **Stephanie L Graff**, Ivor J Percent, Lucio Navarro Gordan, Vijay Manilal Patel, Christian Squillante, Mark Knapp, Daniel Spitz, Christopher Chay, Cameron Blair Harkness, Marc Matrana, Lindsay Carol Overton, Stephen L Richey, Donald A Richards, Habib M H Ghaddar, Sucharu Prakash, Ralph J Hauke, Manish Agrawal, Robert Galamaga, Ronald P Harris, Edward J Crane, David M Waterhouse, Samith T Kochuparambil, Anil Kapoor, Christina Canil, Eric Winkvist, Catherine Sperlich, George Bjarnason, Naveen Basappa, Wolfgang Christian Loidl, Horninger Wolfgang, Renate Pichler, Manuela Schmidinger, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolicka, Jiri Tomasek, Jana Prausova, Thomas Buchler, Petra Holeckova, Philippe Barthelemy, Diego Tosi, Luca Campedel, Aurelien Gobert, Sylvie Negrier, Stephane Oudard, Eric Voog, Sylvie Zanetta, Frédéric Rolland, Jens Bedke, Stefan Siemer, Jan Schleicher, Maria De Santis, Kurt Miller, Manfred Wirth, Lothar Bergmann, Michael Stahler, Philip Ivanyi, Viktor Gruenwald, Christoph Lutz, Jochen Heymanns, Martin Boegemann, Uwe Zimmerman, Gunhild von Amsberg, Sean R McDermott, Richard Bambury, Paul Donnellan, Oscar Breathnach, Raya Leibowitz-Amit, Avishay Sella, Olesya Goldman, Daniel Keizman, Avivit Pe'er, David Sarid, Hovav Nechushtan, Raanan Berger, Victoria Neiman, Fabio Calabro, Paulo Pedrazzoli, Camillo Porta, Francesco Boccardo, Alketa Hamzaj, Ferdinando Riccardi, Ugo DeGiorgi, Sandro Pignata, Giovanni Lo Re, Francesco Massari, Daniele Santini, Vincenzo Emanuele Chiuri, Francesco Carrozza, Roberto Sabbatini, Giuseppe Procopio, Mimma Rizzo, Maria Suelmann, Alfonsus Eertwegh, Johannes van Thienen, Ewa Kalinka-Warzocha, Jacek Jassem, Violetta Sulzyc-Bielicka, Mandziuk Slawomir, Sergey A Tjulandin, Oleg Karyakin, Anna V Alyasova, Boris Ya Alekseev, Vsevolod Matveev, Alexander V Zyryanov, Evgeny I Kopyltsov, Vadim Kozlov, Jose Angel Arranz Ariba, Pablo Borrega Garcia, Miguel Angel Climent Duran, Ignacio Duran Martinez, Begona Perez Valderrama, Emilio Esteban Gonzalez, Francisco Xavier Garcia Del Muro Solans,

- Jesus Garcia Donas, Teresa Alonso Gordo, Jose Pablo Maroto Rey, Begona Mellado, Maria Jose Mendez Vidal, Javier Puente Vazquez, Cristina Suarez Rodriguez, Enrique Grande Pulido, Guillermo Crespo Herrero, Julian Schardt, Jorg Beyer, Natalie Fischer, Hilary Glen, Loretta Sweeney, Jason Lester, Manon R Pillai, Robert E Hawkins, Thomas Powles, Jahangir M Malik, Christy Ralph, Sarah M Rudman, Thomas R Geldart, Aristotelis Bamias, Sofia Baka, Haralabos Kalofonos, Christos Papandreou, Vasilios Georgoulas, Konstantinos Papzisis, Choung-Soo Kim, Sun Young Rha, Seok Soo Byun, Seong I I Seo, Jin Soo Chung, Miso Kim, Bhumsuk Keam, Sung Hoo Hong, Jae Lyun Lee, Se Hoon Park, Tae Gyun Kwon, Ian Douglas Davis, Suet-Lai Shirley Wong, Ian John Byard, Andrew James Weickhardt, Howard Paul Gurney, Jeffrey Chee Hong Goh, Takahiro Osawa, Naoya Masumori, Takuya Koie, Shingo Hatakeyama, Mitsuru Saito, Yoshihiko Tomita, Toshimi Takano, Yuji Miura, Masayoshi Nagata, Go Kimura, Mototsugu Oya, Toshio Takagi, Takatsugu Okegawa, Keichi Kondo, Satoshi Fukasawa, Massfumi Oyama, Masatsugu Iwamura, Akira Komiya, Yoshihisa Matsukawa, Naoto Sassa, Satoshi Tamada, Masahiro Nozawa, Norihito Soga, Satoshi Anai, Kenichi Harada, Atsushi Takamoto, Jun Teishima, Hiroyuki Tsunemori, Masayuki Takahashi, Masatoshi Eto, Hideki Sakai, Takeshi Kishida, Osamu Ukimura
13. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; **IMpassion131 investigators**. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann Oncol*. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. PMID: 34219000.
 - IMpassion131 investigators**: Zhang Q., Xu B., Shao Z., Wang X., Geng C., Yan X., Tong Z., Shen K., Yin Y., Sun T., Yang J., Feng J., Yan M., Wang Y., Liu Q., Zhang S., De Laurentiis M., Santoro A., Guarneri V., Colleoni M., Natoli C., Cortesi L., Placido S., Gianni L., Ferrau F., Livi L., Zambelli A., Del Mastro L., Tonini G., Montemurro F., Bianchi G., Pedersini R., Prete S., Allegrini G., Naso G., Vici P., Loirat D., Mailliez A., Priou F., Tredan O., Dalenc F., Perrin C., Gligorov J., Timar David M., Dohollou N., Teixeira L., Brocard F., Arnaud A., Delaloge S., Spano J.-P., Mansi L., Andrade L., Damian F., Pedrini J., Aleixo S., Hegg R., Junior R., Reinisch M., Schmidt M., Wenzel C., Grischke E.-M., Schneeweiss A., Just M., Harbeck N., Schumacher C., Peters U., Fischer D., Forstbauer H., Liersch R., Warner E., Bouganim N., Doyle C., Price Hiller J., Vandenberg T., Pavic M., Robinson A., Roldan Urgoiti G., Califaretti N., Alacacioglu A., Gumus M., Yalcin B., Cicin I., Kose F., Uygur K., Kaplan M., Cubukcu E., Wardley A., Harries M., Miles D., Doval D., Gupta S., Mohapatra P., Chatterjee S., Ghadyalpatil N., Singhal M., Nag S., Agarwal A., Wolf I., Gal Yam E., Yerushalmi R., Peretz T., Fried G., Ben Baruch N., Katz D., Hamilton E., Kayali F., Brufsky A., Telli M., Wright G., Oyola R., Rakowski T., **Graff S.**, Tjulandin S., Semiglazov V., Aparicio A., Ruiz Borrego M., Merino L., Guerra Martinez J., Lopez E., Yamashita T., Ohtani S., Inoue K., Ito Y., Niikura N., Nakayama T., Sagara Y., Yanagita Y., Kamada Y., Kaneko K., Kaen D., Nervo A., Eniu A., Schenker M., Priester P., Melichar B., Zimovjanova M., Sormova P., Sufliarsky J., Kakalejcik M., Belbaraka R., Errihani H., Le Than D., Pham D., Aravantinos G., Papadimitriou C., Koumakis G., Papandreou C., Podolski P., Tabane K.
 14. Subbiah IM, Markham MJ, **Graff SL**, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R.

- Incidence, Nature, and Consequences of Oncologists' Experiences With Sexual Harassment. *J Clin Oncol*. 2022 Apr 10;40(11):1186-1195. doi: 10.1200/JCO.21.02574. Epub 2022 Jan 28. PMID: 35089804; PMCID: PMC8987225.
15. Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H; **IMpassion050 Trial Investigators**. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. *J Clin Oncol*. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28. PMID: 35763704; PMCID: PMC9426828.
IMpassion050 Trial Investigators: L. Andrade, R.D. Freitas Junior, R. Hegg, J. Pedrini, S. Chia, L. Panasci, L. Provencher, G. Roldan Urgoiti; B. Melichar, M. Palacova; M. Braun, J. Huober, D. Langanke, M. Lux, M. Reinisch, C. Shem, J. Tio, M. Zaiss; M. Cazzaniga, P. Conte, M. De Laurentiis, S. De Placido, F. Montemurro, I. Paris, R. Pedersini, F. Puglisi, A. Santoro; M. Itoh, K. Kaneko, K. Matsumoto, S. Nakamura, N. Niikura, R. Nishimura, S. Ohsumi, M. Okada, A. Osaki, S. Saji, M. Takahashi, Y. Tanabe, T. Yamashita; H.K. Ahn, S-A. Im, K.H. Park, Y.H. Park; Z. Nowecki, I. Symonowicz, M. Jarzab, P. Wysocki; N. Falaleeva, I. Ganshina, P. Krivorotko, R. Safin, D. Stroyakovskii, L. Zhukova; J.L. Alonso, M.I. Blancas Lopez-Barajas, E. Ciruelos Gil, S. Escrivá De Romani Muñoz, A. Gonzalez, F. Henao, B. Hernando Fernandez De Aranguiz, M. Margeli Vila, S. Morales Murillo, M. Muñoz Mateu, M. Ruiz Borrego, P. Sanchez Rovira; Y-C. Chang, S-C. Chen, C-F. Chung, H-C. Wang; **S. Graff**, E. Hamilton, M. Kwa.
 16. **Graff SL**, Subbiah IM, Markham MJ, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R. Frequency, Barriers, Outcomes, and Consequences of Reporting Sexual Harassment in Clinical Oncology. *JNCI Cancer Spectr*. 2023 Jan 3;7(1):pkac081. doi: 10.1093/jncics/pkac081. PMID: 36416149; PMCID: PMC9808769.
 17. Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jalliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M; **monarchE Committee Members**. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. PMID: 36493792.
monarchE Committee: Jimenez MM, Johnston S, Boyle F, Steger GG, Neven P, Jiang Z, Campone M, Huober J, Shimizu C, Cicin I, Wardley A, Tolaney SM, Abuin GG, Zarba J, Lim E, Sant P, Liao N, Christiansen B, Eigeliene N, Martin-Babau J, Ettl J, Mavroudis D, Chiu J, Boer K, Nagarkar R, Paluck-Shimon S, Moschetti L, Sagara Y, Kim SB, Maciel MM, Tjan-Heijnen V, Broom R, Lacko A, Schenker M, Volkov N, Sim Yap Y, Coccia-Portugal M, Angel Garcia Saenz J, Andersson A, Chao TY, Gokmen E, Harputluoglu H, Berzoy O, Patt D, McArthur H, Chew H, Chalasani P, Kaufman P, Tedesco K, **Graff SL**.
 18. **Graff SL**, Wildes T, Duma N, Dizon DS, LoConte NK, Mitchell E, Murphy MC, Perez EA, Temkin SM, Kunz PL, Winkfield KM. Understanding Modern Medical Centers: Beyond Simone-Intersectional Maxims for a New Era. *J Clin Oncol*. 2023 Mar 1;41(7):1350-1358. doi: 10.1200/JCO.22.01060. Epub 2022 Sep 27. PMID: 36166718.
 19. Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri

K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; **CAPitello-291 Study Group**. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. PMID: 37256976.

- CAPitello-291 US Study Group**: Blau SH, Graff S, Mozayen M, Hamilton EP, Hart LL, Landry C, Sharma R, Sharma P, Thara E, Marathe OS, Irvin WJ, Daniel BR, Gudena V, Cao Y, Ademuyiwa FO, Coluzzi P, Rak-Tkaczuk KH, Neidhart J, Klein P, Mina L, Zhao Q, Teplinsky E, Rugo HS, O'Shaughnessy J, Sideras K, Giridhar KV
20. Wang Y, Hacking SM, Li Z, **Graff SL**, Yang D, Tan L, Liu F, Zhang T, Zhao Z, Luo S, Du P, Jia S, Cheng L. Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features: A Clinicopathologic and Molecular Study of 18 Cases. *Am J Surg Pathol*. 2023 Jun 13. doi: 10.1097/PAS.0000000000002073. Epub ahead of print. PMID: 37310016.
 21. **Graff SL**, Principe J, Galvin AM, Fenton MA, Strenger R, Salama L, Bansal R, Dizon DS, Begnoche MH. Evaluating Patient Experience in a Multidisciplinary Breast Cancer Clinic: A Prospective Study. *J Womens Health (Larchmt)*. 2024 Jan;33(1):39-44. doi: 10.1089/jwh.2022.0531. Epub 2023 Nov 23. PMID: 38011006.
 22. Majmudar S, **Graff SL***, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow. *J Med Internet Res*. 2023 Aug 21;25:e47784. doi: 10.2196/47784. PMID: 37603399; PMCID: PMC10477917. (*co-first author)
 23. Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; **BRCA BCY Collaboration**. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA*. 2023 Dec 7:e2325463. doi: 10.1001/jama.2023.25463. Epub ahead of print. PMID: 38059899; PMCID: PMC10704340.

BRCA BCY Collaboration : de Azambuja, Evandro; Molinelli, Chiara; Paesmans, Marianne; Ameye, Lieveke; Amant, Frédéric; Brems, Hilde; Han, Sileny; Hatse, Sigrid; Nevelsteen, Ines; Neven, Patrick; Smeets, Ann; Van Rompuy, Chantal; Wildiers, Hans; Duhoux, Francois; Giugliano, Federica; Criscitiello, Carmen; Borea, Roberto; Arecco, Luca; Chirco, Alessandra; Bini, Federica; Venturelli, Marta; Cortesi, Laura; Ponzzone, Riccardo; Tomasi Cont, Nicoletta; Balmaña, Judith; Graffeo, Rossella; Luna Pais, Helena; Mohar, Alejandro; Palacios, Tamara; Da Ros, Lucia; Miolo, Gianmaria; Garutti, Mattia; Pastò, Brenno; Spazzapan, Simon; Viel, Alessandra; Pérez-Fidalgo, Alejandro; Colombo Bonadio, Renata; Peretz-Yablonski, Tamar; Anghelone, Chiara Annunziata Pasqualina; Della Valle, Angelica; Campanella, Maria; Guarneri, Valentina; Bas, Raphaëlle; Heidelberg, Pierre-Etienne; Tredan, Olivier; de Talouet, Solenne; Bonadona, Valérie; Lasset, Christine; Acheritogaray, Marion; Senechal, Claire; Mariño, Monica; Córdoba, Octavi; Feldman, Didi; Pesce, Romina I.; Allemand, Carol; Riggi, Cecilia; Triarte, Maria

- Belen; Cortés Salgado, Alfonso; Cortes, Javier; Gion, María; Saavedra, Cristina; Rodriguez, Adela; Adamo, Barbara; Prat, Aleix; Hester, Anna; Dunckelmann, Sofia; Harbeck, Nadia; Marhold, Maximilian; Bartsch, Rupert; Mannsbarth, Constantin; Popovic, Lazar; Bozovic-Spasojevic, Ivana; Krivokuca, Ana; Dimitrijevic, Marija; Visani, Luca; Bettazzi, Beatrice; Livi, Lorenzo; Sposetti, Caterina; Sini, Valentina; Rognone, Alessia; Bianchini, Giampaolo; Patricelli, Maria Grazia; Rabaiotti, Emanuela; Gentilini, Oreste; Fontana, Andrea; Acconci, Giulia; Baldacci, Erica; Bianchini, Giulia; Pistelli, Mirco; Linn, Sabine; Kleiterp, Sieta; Moha, Daoud A.; NKI-AvL DataDesk Wetenschappelijke Administrative; Sarin, Rajiv; Sekar, Anberson; Atzori, Francesco; Loi, Francesco; Dessi, Mariele; O'Connor, Sarah; Nesci, Stephanie; James, Paul; Michael, Chris; Couch, Fergus J.; Olson, Janet E.; Larson, Nicole L.; Yadav, Siddhartha; Lopetegui, Nerea; Carey, Lisa A.; Abdou, Yara; Zagami, Paola; Di Rocco, Roberta; Baldassarri, Margherita; Bengala, Carmelo; Mariamidze, Elene; **Graff, Stephanie L.**; Haddad, Stephanie A.; Safran, Emma; Vasconcelos de Matos, Leonor; Ferreira, Arlindo; Negri, Serena; Dell'Oro, Cristina; Inzoli, Alessandra; Costa, Clarissa; Marchetta, Liliana; Lustberg, Maryam; Blansky, Deanna; Jeon, June; Ansari, Norin; Aguilar-y-Mendez, Dione; Woodruff, Teresa K.; Swain, Monique; Miller, Madison; Leach, Richard; Fabi, Alessandra; Palazzo, Antonella; Paris, Ida; Kufel-Grabowska, Joanna; Synowiec, Agnieszka; Hancinova, Miriam; Tarbaj, Lukas; Sokolovic, Emir; Beslija, Semir; Ceric, Timur; Hasanbegović, Berisa; Foulkes, William D; Bianchi, Manuel A.; Tolosa, Pablo; Alvaro, Laura; Eriksson Bergman, Louise; Antone, Nicoleta; Damian, Cristina;
24. Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, **Graff SL**, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. *Ann Oncol.* 2023 Dec;34(12):1141-1151. doi: 10.1016/j.annonc.2023.09.3104. PMID: 38072514.
25. Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordo TA, Kozlov V, Alyasova A, Winkquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; **CLEAR Trial Investigators**. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. *J Clin Oncol.* 2024 Jan 16;JCO2301569. doi: 10.1200/JCO.23.01569. Epub ahead of print. PMID: 38227898.
- CLEAR Trial Investigators:** Robert Motzer, Toni Choueiri, Thomas Hutson, Luke Nordquist, Johanna Chock Bendell, Jamie Merchan, Saby George, Sandy Srinivas, Ulka N Vaishampayan, Elisabeth Heath, Brendan Curti, Andrew Pippas, Subramanya S Rao, Harry Drabkin, Theodore Gourdin, Mehmood H Hashmi, Jason Jung-Gon Suh, Nafisa D Burhani, Ana M Molina, Alan Koletsky, Robert S Alter, Carlos Alemany, Benjamin A Gartrell, Mike Cusnir, Harsha Vyas, Peter Van Veldhuizen, **Stephanie L Graff**, Ivor J Percent, Lucio Navarro Gordan, Vijay Manilal Patel, Christian Squillante, Mark Knapp, Daniel Spitz, Christopher Chay, Cameron Blair Harkness, Marc Matrana, Lindsay Carol Overton, Stephen L Richey, Donald A Richards, Habib M H Ghaddar, Sucharu Prakash, Ralph J Hauke, Manish Agrawal, Robert Galamaga, Ronald P Harris, Edward J Crane, David M Waterhouse, Samith T Kochuparambil, Anil Kapoor,

- Christina Canil, Eric Winkquist, Catherine Sperlich, George Bjarnason, Naveen Basappa, Wolfgang Christian Loidl, Horninger Wolfgang, Renate Pichler, Manuela Schmidinger, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolicka, Jiri Tomasek, Jana Prausova, Thomas Buchler, Petra Holeckova, Philippe Barthelemy, Diego Tosi, Luca Campedel, Aurelien Gobert, Sylvie Negrier, Stephane Oudard, Eric Voog, Sylvie Zanetta, Frédéric Rolland, Jens Bedke, Stefan Siemer, Jan Schleicher, Maria De Santis, Kurt Miller, Manfred Wirth, Lothar Bergmann, Michael Stahler, Philip Ivanyi, Viktor Gruenwald, Christoph Lutz, Jochen Heymanns, Martin Boegemann, Uwe Zimmerman, Gunhild von Amsberg, Sean R McDermott, Richard Bambury, Paul Donnellan, Oscar Breathnach, Raya Leibowitz-Amit, Avishay Sella, Olesya Goldman, Daniel Kejzman, Avivit Pe'er, David Sarid, Hovav Nechushtan, Raanan Berger, Victoria Neiman, Fabio Calabro, Paulo Pedrazzoli, Camillo Porta, Francesco Boccardo, Alketa Hamzaj, Ferdinando Riccardi, Ugo DeGiorgi, Sandro Pignata, Giovanni Lo Re, Francesco Massari, Daniele Santini, Vincenzo Emanuele Chiuri, Francesco Carrozza, Roberto Sabbatini, Giuseppe Procopio, Mimma Rizzo, Maria Suelmann, Alfonsus Eertwegh, Johannes van Thienen, Ewa Kalinka-Warzocha, Jacek Jassem, Violetta Sulzyc-Bielicka, Mandziuk Slawomir, Sergey A Tjulandin, Oleg Karyakin, Anna V Alyasova, Boris Ya Alekseev, Vsevolod Matveev, Alexander V Zyryanov, Evgeny I Kopyltsov, Vadim Kozlov, Jose Angel Arranz Arijia, Pablo Borrega Garcia, Miguel Angel Climent Duran, Ignacio Duran Martinez, Begona Perez Valderrama, Emilio Esteban Gonzalez, Francisco Xavier Garcia Del Muro Solans, Jesus Garcia Donas, Teresa Alonso Gordo, Jose Pablo Maroto Rey, Begona Mellado, Maria Jose Mendez Vidal, Javier Puente Vazquez, Cristina Suarez Rodriguez, Enrique Grande Pulido, Guillermo Crespo Herrero, Julian Schardt, Jorg Beyer, Natalie Fischer, Hilary Glen, Loretta Sweeney, Jason Lester, Manon R Pillai, Robert E Hawkins, Thomas Powles, Jahangir M Malik, Christy Ralph, Sarah M Rudman, Thomas R Geldart, Aristotelis Bamias, Sofia Baka, Haralabos Kalofonos, Christos Papandreou, Vasilios Georgoulas, Konstantinos Papzisis, Choung-Soo Kim, Sun Young Rha, Seok Soo Byun, Seong I I Seo, Jin Soo Chung, Miso Kim, Bhumsuk Keam, Sung Hoo Hong, Jae Lyun Lee, Se Hoon Park, Tae Gyun Kwon, Ian Douglas Davis, Suet-Lai Shirley Wong, Ian John Byard, Andrew James Weickhardt, Howard Paul Gurney, Jeffrey Chee Hong Goh, Takahiro Osawa, Naoya Masumori, Takuya Koie, Shingo Hatakeyama, Mitsuru Saito, Yoshihiko Tomita, Toshimi Takano, Yuji Miura, Masayoshi Nagata, Go Kimura, Mototsugu Oya, Toshio Takagi, Takatsugu Okegawa, Keichi Kondo, Satoshi Fukasawa, Masafumi Oyama, Masatsugu Iwamura, Akira Komiya, Yoshihisa Matsukawa, Naoto Sassa, Satoshi Tamada, Masahiro Nozawa, Norihito Soga, Satoshi Anai, Kenichi Harada, Atsushi Takamoto, Jun Teishima, Hiroyuki Tsunemori, Masayuki Takahashi, Masatoshi Eto, Hideki Sakai, Takeshi Kishida, Osamu Ukimura
26. Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, **Graff SL**, Hall MJ, Borghaei H, Hoon DS, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers. *Nat Cancer*. 2024 Mar 25. doi: 10.1038/s43018-024-00752-x. Epub ahead of print. PMID: 38528112.
 27. Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, **Graff SL**, Antonarakis ES, Goel S, Sledge G, Lopes G. The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.

- Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. PMID: 38672653; PMCID: PMC11049662.
28. Kim KW, Lopresti M, **Graff SL**, Witherby S, Dizon DS, Fenton MA. Fulfilling the Role of a Parent While Undergoing Treatment for Cancer: A Review of the Literature and the Potential Impact of Childcare Support on Cancer Outcomes. *Am J Clin Oncol*. 2024 Sep 1;47(9):445-447. doi: 10.1097/COC.0000000000001102. Epub 2024 Apr 23. PMID: 38651681.
 29. Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Peeters MV, Poortmans P, Mann RM, **Graff SL**, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). *Eur J Nucl Med Mol Imaging*. 2024 Jul;51(9):2706-2732. doi: 10.1007/s00259-024-06696-9. Epub 2024 May 14. PMID: 38740576.
 30. Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH; **and Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel**. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. *J Clin Oncol*. 2024 May 20;JCO2400886. doi: 10.1200/JCO.24.00886. Epub ahead of print. PMID: 38768407.
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel: Mariana Chavez-MacGregor, Amy H Comander, Zoneddy Dayao, Andrea Eisen, Rachel A Freedman, Ragisha Gopalakrishnan, **Stephanie L Graff**, Michael J Hassett, Tari A King, Gary H Lyman, Gillian Rice Maupin, Cheryl L Perkins, Melinda L Telli, Maureen E Trudeau, Antonio C Wolff, Sharon H Giordano
 31. Arecco L, Bruzzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, Hilbers FS, Pogoda K, Carrasco E, Punie K, Bajpai J, Agostinetti E, Lopetegui-Lia N, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Curigliano G, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Couch FJ, Dieci MV, Matikas A, Rozenblit M, Aguilar-Y Méndez D, De Marchis L, Puglisi F, Fabi A, **Graff SL**, Witzel I, Rodriguez Hernandez A, Fontana A, Pesce R, Duchnowska R, Pais HL, Sini V, Sokolović E, de Azambuja E, Ceppi M, Blondeaux E, Lambertini M. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. *Ann Oncol*. 2024 Sep;35(9):792-804. doi: 10.1016/j.annonc.2024.06.009. Epub 2024 Jun 20. PMID: 38908482..
 32. **Graff SL**, Freeman EC, Roach M, Wilson R, Cagle C, Lunsford S, Maravic MC, Fairley R, Gullatte M, Stemland J, Wochal P, Katz J, Hoffner B, Scott JM, May SG. Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery. *JCO Oncol Pract*. 2024 Sep 19;OP2400228. doi: 10.1200/OP.24.00228. Epub ahead of print. PMID: 39298690.
 33. Bansal R, Adeyelu T, Elliott A, Walker P, Bustos M, Rodriguez E, Accordini ML, Meisel J, Gatti- Mays M, Hsu E, Lathrop K, Kaklamani V, Oberley M, Sledge G, Sammons SL, **Graff SL**. Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer. *Breast Cancer Res Treat* (2024). <https://doi-org.revproxy.brown.edu/10.1007/s10549-024-07495-4>
 34. Wang Y, Liu L, **Graff SL**, Cheng L. Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients. *Histopathology*. 2025 Feb;86(3):472-477. doi: 10.1111/his.15345. Epub 2024 Oct 22. PMID: 39435750.
 35. Bansal R, Adeyelu T, Elliott A, Tan AR, Ribeiro JR, Meisel J, Oberley MJ, **Graff SL**, Sledge GW Jr, Grilley-Olson JE, Sammons SL, Rosenberger LH. Genomic Landscape of Malignant

- Phyllodes Tumors Identifies Subsets for Targeted Therapy. *JCO Precis Oncol.* 2024 Dec;8:e2400289. doi: 10.1200/PO.24.00289. Epub 2024 Dec 5. PMID: 39637336; PMCID: PMC11634179.
36. Kalinsky K, Bianchini G, Hamilton E, **Graft SL**, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Muñoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. *J Clin Oncol.* 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18. PMID: 39693591.
 37. Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, **Graft SL**, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H. Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. *Cancer Cell.* 2024 Dec 9;42(12):1985-1987. doi: 10.1016/j.ccell.2024.10.017. Epub 2024 Nov 21. PMID: 39577419.
 38. Wang Y, Liu L, **Graft SL**, Cheng L. Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer. *Histopathology.* 2024 Dec 17. doi: 10.1111/his.15395. Epub ahead of print. PMID: 39687977.
 39. Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; **DESTINY-Breast06 Trial Investigators**. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. *N Engl J Med.* 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. PMID: 39282896.
- DESTINY-Breast06 Trial Investigators:** Straich, G, Cundem, J, Constanze, M, Casarinl, I, Casainuove, M, Daniele, S, Ostoich, S, Escudero, M, Palazzo, P, Bella, S, Fein, L, Varela, M, Salvatierra, A, Mando, P, Korbenfeld, E, Oarbaos, G, Rosselti, G, Luen, S, Lim, E, van der Westhuizen, A, Baron-Hay, S, Moore, M, Morris, M, Miidieton, K, Kiely, B, Murray, N, Moore, M, Ganju, V, McCarthy, N, Redfern, A, Murray, N, Balic, M, Bartsch, R, Denison, U, Egle, D, Widiers, H, Taylor, D, Dirtx, L, Duhoux, F, Deteu, I, Denys, H, Gombos, A, Mebis, J, Papadimitriou, K, Collignon, J, Canon, J, Schotte, K, De Cuyper, E, Mattar, A, Souza, C, Pires, L, Matias, D, Alves, D, Pedrini, J, Pentagna, P, Chaves, F, de Padua, C, Barrios, C, Santos, E, Gagliato, D, Bedard, P, Brezden-Masley, C, Lohrisch, C, Joy, A, Asselah, J, Warner, E, Henning, J, Panuganty, V, Pavic, M, Friedmann, J, Hu, X, Ouyang, Q, Liao, N, Liu, J, Wang, S, Zhang, S, Pang, D, Yang, J, Pan, Y, Zang, A, Tan, A, Zhang, S, Wang, S, Zhang, Z, Chen, W, Jiang, Z, Yan, M, Tong, Z, Wang, X, Fu, P, Cheng, Y, Wang, X, Fang, F, LI, W, Zhang, Q, Yin, Y, Feng, J, Wang, S, Wu, X, Wang, J, Sun, M, Sun, T, Teng, Y, Hao, B, Ye, C, Zhang, L, Zheng, H, Xie, X, Ling, X, Huang, H, Wu, X, Wu, Y, Su, H, Wang, C, Wu, C, Tao, M, Yang, J, Li, H, Xu, B, Shen, K, Wang, H, Chen, X, LI, H, Hu, C, Hu, B, Andersson, M, Vistisen, A, Kodahl, A, Langkjer, S, Iversen, E, Glavicic, V, Simon, H, Brain, E, Doholiou, N, Ferrero, J, Frenel, J, Grenier, J, Jacot, W, Ladoire, S, Lefeuvre, C, Lévy, C, Meynard, G, Pierga, J, Pistilli, B, Vegas, H, Viret, F, Bonnin, N, Hardy-Bessard, A, Bourgeois, H, Park-Simon, T, Hartkopf, A, Blohmer, J, Müller, V, Zaiss, M, Tio, J, Nusch, A, Kotzur, F, Aktas, B, Harbeck, N, Wimberger, P, Hänle, C, Horvath, Z, Sipocz, I, Csôsi, T, Mészáros, E, Rubovszky, G, Mezel, K, Pápai, Z, Homnyak, L, Bálint, A, Furka, A, Uhlyarik, A, Dank, M, Gupta, S, Doval, D, Kataria, S, Raut, N, Ghosh, J, Arya, D, Keechilat, P, Jain, P, Limaye, S, Warriar, N, Rauthan, A, Rona, J, Mukherjee, K, Gupta, R, Thomas, B, Panchal, H, Coca, P, B. K., V, Gundeti, S, Gupta, D, Kate, S, Dodagoudar, C, Patel, A, Batra, A, Molho, R, Yerushalmi, R, Lubovsky, S, Sonnenblick, A, Paluch-Shimon, S, Kuchuk, I, Goldwasser, H, Curigliano, G, Guarneri, V,

- Biganzoli, L, Mosconi, A, Frassoldati, A, De Placido, S, Bianchini, G, Ricclardi, G, Puglisi, F, Montemurro, F, Musolino, A, Coltelli, L, Del Mastro, L, Pascoletti, G, Bianchi, G, Caremoli, E, Tamburini, E, De Laurentiis, M, Santoro, A, Yonemori, K, Itoh, M, Inoue, K, Niikura, N, Sagara, Y, Yamashita, T, Tsurutani, J, Hattori, M, Sudo, K, Naito, Y, Miyoshi, Y, Nakayama, T, Aogi, K, Tokunaga, E, Iwasa, T, Takano, T, Shien, T, Takahashi, M, Tsuneizumi, M, Saito, M, Kaneko, K, Matsumoto, K, Sangal, T, Tsugawa, K, Ishikawa, T, Ishiguro, H, Kitagawa, C, Mizuno, T, Ishida, T, Nakamura, R, Futamura, M, Kamada, Y, Escobar Penagos, J, Vazquez Limón, J, Villalobos Valencia, R, Ramirez Godinez, F, Melendez Mier, G, Lara, J, Diaz, H, Kuri Exsome, R, Arce, C, Garnica, G, Martinez Herrera, J, Camacho Limas, C, Dezentjé, V, Jager, A, Erdkamp, F, Heijns, J, Hamming, L, Siemerink, E, Wysocki, P, Lacko, A, Zurawski, B, Mruk, A, Ulanska, M, Nowecki, Z, Kukielka-Budny, B, Kwiatkowski, M, Kalinka, E, Cardoso, F, Braga, S, Cassiano Neves, M, Gouvela, E, Nave, M, Branco, F, Augusto, I, Sousa, A, Jung, K, Lee, K, Park, K, Sohn, J, Park, Y, Im, S, Chae, Y, Suh, K, Lee, M, Arkhipov, A, Fedenko, A, Kislov, N, Makarova, Y, Nechaeva, M, Mukhametshina, G, Zhukova, L, Kudryavtsev, I, Krivorotko, P, Frolova, M, Moiseyenko, V, Udovitsa, D, Khokhlova, S, Laskov, M, Stroyakovskiy, D, Karnaukhov, I, Mochalova, A, Artamonova, E, Gornastolev, D, Penkov, K, Leonov, A, Semiglazova, T, Sekacheva, M, Basulaiman, B, Alwbari, A, Abdel Hafeez, N, Refae, A, Al-Foheidi, M, Al-Twelgeri, T, Mohammed, S, Dent, R, Ow, S, Bharwanl, L, Ang, C, Ngo Su Mien, L, Wong, K, Saura, C, Zamora Auñón, P, Alvarez López, I, De la Haba, J, Alonso Romero, J, Ruiz Borrego, M, Lopez Marti, M, De la Cueva Sapiña, H, Antolin Novoa, S, Adamo, B, López-Tarruella Cobo, S, Gil Gil, J, Lindman, H, Narbe, U, Klint, L, Andersson, A, Valachis, A, von Wachenfeldt Våppling, A, Person, H, Chao, T, Chang, Y, Tseng, L, Huang, C, Chung, W, Chen, W, Wang, H, Chen, S, Baird, R, Mukesh, M, Armstrong, A, Borley, A, Ahmed, S, Hicks, J, Dubey, S, Twelves, C, Hall, P, Paterson, F, Nathan, M, Scatchard, K, Guppy, A, Thomson, A, McAvan, L, Tsalic, M, O'Shaughnessy, J, Hilton, C, Nangia, J, Boccia, R, Stewart, D, D'Olimpio, J, All, H, Beck, T, Santa-Maria, C, Durna, L, Seneviratne, L, Ernst, B, Dasgupta, A, Oh, S, Vulchi, M, McCormick, K, Elkhanany, A, Borges, V, Sharma, P, Schott, A, Huston, A, Rexer, B, Bagegni, N, Bardia, A, Schwartzberg, L, Agarwal, L, Williams, N, Qamar, R, Wisinski, K, Fox, J, Patt, D, Krop, L, Nangia, J, Giridhar, K, Osborne, C, Advanl, P, Danso, M, Abou-Hussein, A, McCormick, K, **Graff, SL**, Sajid, S, Guerin, B
40. Strandberg J, Louie A, Lee S, Hahn M, Srinivasan P, George A, De La Cruz A, Zhang L, Hernandez Borrero L, Huntington KE, De La Cruz P, Seyhan AA, Koffer PP, Wazer DE, DiPetrillo TA, **Graff SL**, Azzoli CG, Rounds SI, Klein-Szanto AJ, Tavora F, Yakirevich E, Abbas AE, Zhou L, El-Deiry WS. TRAIL agonists rescue mice from radiation-induced lung, skin or esophageal injury. *J Clin Invest*. 2025 Jan 14:e173649. doi: 10.1172/JCI173649. Epub ahead of print. PMID: 39808500.
 41. Groheux D, Vaz SC, de Geus-Oei LF, Dibble EH, Ulaner GA, Cook GJR, Hindie E, Poortmans P, Mann RM, Jacene H, Woll JPP, Rubio IT, Peeters MV, **Graff SL**(*co-senior author), Cardoso F*; [18F]FDG-PET/CT in staging and restaging patients with breast cancer, *J Clin Oncol*. 2025 Mar 25;JCO2401945. doi: 10.1200/JCO-24-01945. Epub ahead of print. PMID: 40132148.
 42. **Graff SL**, Tolaney SM, Hart L, Razavi P, Janni W, Schwartzberg L, Danyliv A, Akdere M, Ferrusi I, Adhikary R, O'Shaughnessy J. Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer. *Cancer*. 2025 Apr 1;131(7):e35817. doi: 10.1002/cncr.35817. PMID:

40159245; PMCID: PMC11955092.

43. Jayachandran P, Deshmukh SK, Wu S, Ribeiro JR, Kang I, Xiu J, Farrell A, Battaglin F, Spicer DV, Soni S, Zhang W, Ashouri K, Millstein J, Ma CX, **Graff SL**, Radovich M, Sledge GW Jr, Lenz HJ, Roussos Torres ET. Association of Androgen Receptor Expression With Tumor Immune Landscape and Treatment Outcomes of Patients With Breast Cancer. *JCO Precis Oncol*. 2025 Apr;9:e2400459. doi: 10.1200/PO-24-00459. Epub 2025 Apr 28. PMID: 40294352.
44. O'Shaughnessy J, Tolane SM, Yardley D, Hart L, Razavi P, Fasching PA, Janni W, Schwartzberg L, Kim J, Akdere M, McDermott C, Khakwani A, Pathak P, **Graff SL**. Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer. *Breast*. 2025 Mar 7;81:104437. doi: 10.1016/j.breast.2025.104437. Epub ahead of print. PMID: 40157276; PMCID: PMC11995083.
45. Lambertini M, Perachino M, Blondeaux E, Delucchi V, Bernstein Molho R, Frank S, Paluch-Shimon S, Linn S, Di Meglio A, Peccatori F, Moore HCF, Parokonnaya A, Renaud T, Rodriguez Wallberg KA, Partridge AH, Pogoda K, Ferrari A, Wildiers H, Toss A, Rousset-Jablonski C, Kim HJ, Varela M, Cordoba O, Tanase Damian C, Marhold M, Fabi A, **Graff SL**, Rodriguez-Hernandez A, Okano M, Duchnowska R, Luna Pais H, Di Rocco R, Azim HA, Mariamidze E, Kourie HR, Arecco L, Carrasco E, Agostinetto E, Balmana J, Saura C. Safety of Having a Subsequent Pregnancy After Prior Diagnosis of Breast Cancer During Pregnancy in Young BRCA Carriers. *ESMO Open* 2024 July 14;10(8): 105513 <https://doi.org/10.1016/j.esmoop.2025.105513>.
46. Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy JA, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O'Regan R, Santarsiero L, Akdere M, Ye F, Scotchmer A, **Graff SL**. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis. *ESMO Open*. 2025 Jun 13;10(6):105304. doi: 10.1016/j.esmoop.2025.105304. Epub ahead of print. PMID: 40516131.

OTHER PEER-REVIEWED PUBLICATIONS

47. **Schutt, SL**. The Puppet Show. *Missouri Medicine*. April 2001: 98(144-5)
48. Cook JW, Dillmon M, **Graff SL**, Pentz RD, Srivastava R, Close JL. Caring for Colleagues and Loved Ones With Cancer. *Am Soc Clin Oncol Educ Book*. 2018 May 23;38:903-908. doi: 10.1200/EDBK_201451. PMID: 30231376.
49. **Graff, SL**. Perspective: Cost Barriers and Beyond. *Oncology* (Williston Park) 33 (2): 54-7 Feb 2019
50. **Graff SL**. The Cattle Don't Care. *J Clin Oncol*. 2019 May 1;37(13):1136-1138. doi: 10.1200/JCO.19.00255. Epub 2019 Mar 18. PMID: 30883247.
51. LaCasce A, **Graff SL**, Gao J, Close J, Boulmay B. Preparing Fellows for Graduation: Perspectives on Career Guidance. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39:609-614. doi: 10.1200/EDBK_242603. Epub 2019 May 17. PMID: 31099656.
52. Ersek JL, **Graff SL**, Arena FP, Denduluri N, Kim ES. Critical Aspects of a Sustainable Clinical Research Program in the Community-Based Oncology Practice. *Am Soc Clin Oncol Educ Book*. 2019 Jan;39:176-184. doi: 10.1200/EDBK_238485. Epub 2019 May 17. PMID: 31099620.

53. **Graff SL.** Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy. *JCO Oncol Pract.* 2021 Nov 15;OP2100720. doi: 10.1200/OP.21.00720. Epub ahead of print. PMID: 34780307.
54. Anampa-Guzmán A, Freeman-Daily J, Fisch M, Lou E, Pennell NA, Painter CA, Sparacio D, Lewis MA, Karmo M, Anderson PF, **Graff SL**; Collaboration for Outcomes using Social Media in Oncology. The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator. *JCO Oncol Pract.* 2022 Aug;18(8):578-583. doi: 10.1200/OP.21.00763. Epub 2022 Mar 28. PMID: 35344398; PMCID: PMC9377686.
55. Chidharla A, Utengen A, Attai DJ, Drake EK, van Londen GJ, Subbiah IM, Henry E, Murphy M, Barry MM, Manochakian R, Moerdler S, Loeb S, **Graff SL**, Leyfman Y, Thompson MA, Markham MJ. Social Media and Professional Development for Oncology Professionals. *JCO Oncol Pract.* 2022 Aug;18(8):566-571. doi: 10.1200/OP.21.00761. Epub 2022 Mar 21. PMID: 35312343; PMCID: PMC9377722.
56. **Graff SL.** People Like Us. *J Clin Oncol.* 2023 Feb 1;41(4):931-932. doi: 10.1200/JCO.22.01835. Epub 2022 Nov 8. PMID: 36346963.
57. Sagaityte E, Dowd RS, Lane K, **Graff SL**, Toms SA. The Role of RNA Epitranscriptomics and the RNA Fat Mass and Obesity-Associated Demethylase in Triple Negative Breast Cancer. *Advances in Breast Cancer Research*, 2023: 12, 27-50. doi: 10.4236/abcr.2023.122004.
58. Vaz SC, **Graff SL**, Ferreira AR, Debiase M, de Geus-Oei L-F. PET/CT in Patients with Breast Cancer Treated with Immunotherapy. *Cancers (Basel).* 2023 May 5;15(9):2620. doi: 10.3390/cancers15092620. PMID: 37174086; PMCID: PMC10177398.
59. **Graff SL**, Yang F, Abdou Y. Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer. *Clin Breast Cancer.* 2023 May 13:S1526-8209(23)00108-8. doi: 10.1016/j.clbc.2023.05.003. Epub ahead of print. PMID: 37407378.
60. Prioritization of Antineoplastic Agents in Limited Supply, American Society of Clinical Oncology Clinical Guidance Statement, **ASCO Drug Shortages Task Force**. Published online May 22, 2023 <https://old-prod.asco.org/practice-patients/practice-support/drug-shortages/clinical-guidance>
ASCO Drug Shortages Task Force: Aparicio A, Campbell T, Castiel M, Colevas D, Diaz M, Eng C, **Graff SL**, Gregg X, Hoffman-Censits J, Jeames S, Briseno Kenney L, Klix M, Lee N, Markham MJ, McKenzie N, Pant S, Persing B, Rugo H, Saeed A, Santos E, Scalici J, Shroff R, Symington B, Tagawa S, Teplinsky E, Traina T, Ulahannan S, Wilfong L, Winegarden JD, Zarwan C
 Breast Cancer Guidance, Prioritization of Antineoplastic Agents in Limited Supply, American Society of Clinical Oncology Clinical Guidance Statement, ASCO Drug Shortages Breast Cancer Task Force. Published online June 12, 2023 at <https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/practice-patients/documents/2023-ds-breast-recs.pdf>
ASCO Breast Cancer Drug Shortages Task Force: Deboer R, Zarwan C, Rugo H, **Graff SL**, Park K, Nahleh Z, Telli M, Kaufmann T, Nackos E, Thompson A, Robson ME, Ruddy KJ, Wright J, Allison K, Anders C, Cortes J, Puztai L, Spears P, Gralow J, Traina T, Geisel R, MacGregor Chavez M
61. Haddad S, Dizon DS, Graff SL. Sequencing Systemic Therapy in Hormone-Receptor Positive Metastatic Breast Cancer: A Modern Paradigm. *J Chinese Clinical Oncology*, 2023. Published

- online Aug 10, 2023. doi: 10.21037/cco-23 <https://cco.amegroups.org/article/view/116368>
62. Fenton MA, Tarantino P, **Graff SL**. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. *Curr. Oncol.* 2023, 30(12), 10211-10223; <https://doi.org/10.3390/curroncol30120743>
 63. Ali A, **Graff SL**. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan. *Curr Oncol Rep.* 2023 Dec 13. doi: 10.1007/s11912-023-01478-2. Epub ahead of print. PMID: 38091201
 64. **Graff SL**, McGinn C, Showalter JR. Improving Outcomes for Women With Metastatic HER2-Positive and HER2-Low Breast Cancer. *J Adv Pract Oncol.* 2024 Apr;15(3):187-190. doi: 10.6004/jadpro.2024.15.3.6. Epub 2024 Apr 1. PMID: 39297071; PMCID: PMC11406316. *Journal of the Advanced Practitioner in Oncology (JADPRO)* <https://doi.org/10.6004/jadpro.2024.15.3.6>
 65. Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, **Graff SL**, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF. Joint EANM-SNMMI guidelines on the role of 2-[¹⁸F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines. *Eur J Nucl Med Mol Imaging.* 2024 Jul;51(9):2701-2705. doi: 10.1007/s00259-024-06694-x. PMID: 38693453.
 66. Gobbo M, Joy J, Guedes H, Shazib MA, Anderson C, Abdalla-Aslan R, Peechatanan K, Lajolo C, Nasir KS, Gueiros LA, Nagarajan N, Hafezi Motlagh K, Kandwal A, Rupe C, Xu Y, Ehrenpreis ED, Tonkaboni A, Epstein JB, Bossi P, Wardill HR, **Graff SL**. Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents. *Expert Opin Pharmacother.* 2024 May 29:1-16. doi: 10.1080/14656566.2024.2354451. Epub ahead of print. PMID: 38808634.
 67. Hsu E, Arezo SM, **Graff SL**. Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. *Curr. Treat. Options in Oncol.* (2024). <https://doi-org.revproxy.brown.edu/10.1007/s11864-024-01258-5>
 68. Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, Hindié E, Pilkington Woll JP, Jacene H, Rubio IT, Vrancken Peeters MJ, Dibble EH, de Geus-Oei LF, **Graff SL**, Cardoso F. Role of [¹⁸F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. *Breast.* 2024 Sep 12;78:103806. doi: 10.1016/j.breast.2024.103806. Epub ahead of print. PMID: 39303572; PMCID: PMC11440802.
 69. **Graff SL**, Tinianov S, Kalinsky K. "Nailing down" risk and improving outcomes in early-stage breast cancer. *J Natl Cancer Inst.* 2024 Nov 22:djae278. doi: 10.1093/jnci/djae278. Epub ahead of print. PMID: 39576672.
 70. El-Deiry WS, Bresson C, Wunder F, Carneiro BA, Dizon DS, Warner JL, **Graff SL**, Azzoli CG, Wong ET, Cheng L, Mani SA, Safran HP, Williams C, Meissner T, Solomon B, Rubin E, Porgador A, Berchem G, Saintigny P, Onn A, Bar J, Berger R, Gantenbein M, Chen Z, Souza CP, Reis RMV, Sekacheva M, Cervantes A, Dahut WL, Annunziata CM, Gober K, Musallam KM, Al-Shamsi HO, Abu-Gheida I, Salazar R, Limaye S, Aref AT, Reddel RR, Homsí MUA, Rouf A, Dermime S, Suwaidi JA, Vlad C, Buiga R, Omari AA, Abdel-Razeq H, Oñate-Ocaña LF, Nielsen FC, Graham L, Rueter J, Joshua AM, Girda E, Libutti S, Riedlinger G, Salem ME, Farhangfar CJ, Mesa RA, Faltas BM, Elemento O, Pramesh CS, Sengar M, Aoyama S, Ikeda S, Berindan-Neagoe I, Gaddipati H, Kulkarni M, Auzias E, Gerogianni M, Wolikow N, Istolainen S, Schlafrig P, Frankel NZ, Ferraro AR, Palma J, Gimenez AP, Hernando-Calvo A, Felip E, Tsimberidou AM, Herbst RS, Tabernero J, Schilsky RL, Liu J, Lussier Y, Raynaud J, Batist G, Magidi S, Kurzrock R. Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients. *Oncotarget.* 2025

- Mar 12;16:140-162. doi: 10.18632/oncotarget.28703. PMID: 40073368; PMCID: PMC11907938.
71. Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, **Graff SL**, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. TROPION-Breast05: A randomized phase 3 study of datopotamab deruxtecan (Dato-DXd) with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. *Therapeutic Advances in Medical Oncology*. 2025;17. doi:10.1177/17588359251327992
 72. Ryspayeva D, Seyhan AA, MacDonald WJ, Purcell C, Roady TJ, Ghandali M, Verovkina N, El-Deiry WS, Taylor MS, **Graff SL**. Signaling pathway dysregulation in breast cancer. *Oncotarget*. 2025 Mar 13;16:168-201. doi: 10.18632/oncotarget.28701. PMID: 40080721; PMCID: PMC11906143.
 73. Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, Melosky B, Niikura N, Yap TA, Kim SS, Rajagopalan R, Fairhurst RM, **Graff SL*** (*co-senior author), Rugo HS*. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. *Oncologist*. 2025 Mar 10;30(3):oyaf031. doi: 10.1093/oncolo/oyaf031. PMID: 40139260; PMCID: PMC11942793.
 74. Patel SR, **Graff SL**. Invisible in the Metrics of Academic Oncology. *JCO Oncol Pract*. 2025 Jun 20;OP2500283. doi: 10.1200/OP-25-00283. Epub ahead of print. PMID: 40540705.
 75. Stubbs NM, Roady TS, Schwermann MP, Eteshola EO, MacDonald WJ, Purcell C, Ryspayeva D, Verovkina D, Tajiknia V, Ghandali M, Vong V, Lanigan L, Lawler S, Holder SL, Carneiro BA, Cheng L, Safran HP, **Graff SL**, Dizon DS, Mani SA, Seyhan AA, Sobhol RW, Wong ET, Clark CC, Gokaslan Z, Taylor MS, Rivers BM, El-Deiry WS. Acquired Resistance in Molecularly-Targeted Therapies, *Cancer Drug Resist*. 2025;8:27 DOI: 10.20517/cdr.2024.189.
 76. Sekeres MA, Abel GA, Gilligan T, **Graff SL**, Kalemkerian GP, Korones DN, Loren AW, McNeil C, Riches JC. The Art of the Art of Oncology. *J Clin Oncol*. 2025 Jul 14;JCO2501205. doi: 10.1200/JCO-25-01205. Epub ahead of print. PMID: 40658914.
 77. Adams M, Lock YJ, Steckler A, Kumar S, Dizon S, Duffy CM, Fenton MA, Sauerbrun-Cutler MT, **Graff SL**. Pregnancy and Parenthood after Breast Cancer. *Accepted 17 JUN 2025, Current Breast Cancer Reports*
 78. **Graff SL**. Brown Paper Bags. *J Clin Oncol*. 2025 Aug 28;JCO2501474. doi: 10.1200/JCO-25-01474. Epub ahead of print. PMID: 40875964.

BOOKS AND BOOK CHAPTERS

1. Stages of IB to IIIA non-small cell lung cancer: the case for induction versus adjuvant chemotherapy, Multidisciplinary Approach to Lung Cancer. **Graff SL**, Kelly K. Demos Medical Publishing, 2011
2. Dr. Susan Love's Breast Book, 7th Edition. Love SM, Love E. with contributing authors **Graff SL**, Green L. Hancette Go. November 7, 2023. ISBN-10: 0306833255, ISBN-13: 978-0306833250
3. Breast Cancer, Chapter 11. Graves T, **Graff SL**, Hepel J, Fenton MA, Chudasama R, Dizon DS. The Principles and Practice of Gynecologic Oncology, 8th Edition. Chi D, Khabele D, Dizon DS, Yashar CM. Wolters Kluwer Health, Inc. Published May 31, 2024. ISBN/ISSN: 9781975183271
4. "There's Never a Good Time: Navigating Graduate Medical Education while Pregnant" and "Appendix B: Out of Office Replies" **Graff SL**. Parenting While Ph.Ding: Surviving

and Improving the Working Conditions of Graduate Student Parents, Jenna Morton-Aiken, Jackie Hoermann-Elliott. *Publication July 15, 2025, Rutgers University Press, ISBN-10 1978843763; ISBN-13 978-1978843769 Hardcover and Paperback*

MULTICENTER TRIALS

5. Phase I/II study of the combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma (NCT01496118) Site Sub-Investigator
 - Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. *Haematologica*. 2015 May;100(5):670-6. doi: 10.3324/haematol.2014.119735. Epub 2015 Feb 20. PMID: 25710456; PMCID: PMC4420216.
6. GC-627-02: A Phase II, Randomized, Multi-Center, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. (NCT03252431; Generon) Principal Investigator
 - Glaspy J, Tang T, Ruttly D, Yan X, Bondarenko I, Krasnozhan D; A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (filgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. *Blood* 2014;124(21):1584. doi: <https://doi.org/10.1182/blood.V124.21.1584.1584>
7. A Randomized, Double-Blind, Multi-center, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin. Site Sub-Investigator
 - Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. *Neuroendocrinology*. 2015;102(1-2):18-25. doi: 10.1159/000381715. Epub 2015 Mar 21. PMID: 25824001.
8. A Randomized, Open-Label Phase 3 Study of MM-398 versus 5-Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer. (Merrimack Pharmaceuticals; NCT01494506) Sub-Investigator
 - Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartzmann G, Siveke JT, Braithe F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. *Lancet*. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29.
9. A Phase II Study of the Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor (GIST). Site Sub-Investigator
 - Bendell JC, Bauer TM, Lamar R, Joseph M, Penley W, Thompson DS, Spigel DR, Owera R, Lane CM, Earwood C, Burris HA 3rd. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. *Cancer Invest*. 2016 Jul 2;34(6):265-70. doi: 10.1080/07357907.2016.1193746. Epub 2016 Jul 5. PMID: 27379708.

10. A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer (BRE 274, Innocrine Pharmaceuticals; NCT02580448), Principal Investigator.
 - Gucalp A, Danso MA, Elias AD, Bardia A, Ali HY, Potter D, Gabrail NY, Haley BB, Khong HT, Riley EC, Ervin L, Eisner JR, Baskin-Bey E, Moore ER, and Traina TA; Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. *Journal of Clinical Oncology* 2017 35:15_suppl, 1102
11. A Phase III, randomized, double-blind placebo-controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER-2 negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment. (BELLE2 NCT01610284), Site Principal Investigator
 - Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30
12. A Multinational, Multicenter, Randomized, Phase 3 Study of TeseTaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane, (BRE 303) Site Principal Investigator
 - O'Shaughnessy J, Piccart M, Schwartzberg LS, Cortes J, Harbeck N, Seock-Ah I, Rugo HS, Untch M, Yardley DA, Bondarenko I, Chan S, Dieras V, Pegram MD, Kroll S, O'Connell JP, Wei T, Tang K, Seidman AD. CONTESSA: A multinational, multicenter, randomized, phase III registration study of teseTaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. *Journal of Clinical Oncology* 2019 37:15_suppl, TPS1107-TPS1107
13. Phase IIA Study of Transtuzumab/pertuzumab, erlotinib, vemurafenib and Vismodegib in advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents (NCT02091141), Site Principal Investigator
 - Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIA Multiple Basket Study. *J Clin Oncol.* 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. Erratum in: *J Clin Oncol.* 2019 Feb 1;37(4):360. PMID: 29320312.
14. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER-2 Negative Breast Cancer. (BRE-197, NCT 01527487). Site Principal Investigator
 - Yardley DA, Shipley D, Zubkus J, Wright GL, Ward PJ, Mani A, Shastry M, Finney L, DeBusk L, Hainsworth JD. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy

- in Operable HER2-negative Breast Cancer. *Clin Breast Cancer*. 2019 Feb;19(1):1-9. doi: 10.1016/j.clbc.2018.08.006. Epub 2018 Aug 23. PMID: 30245148.
15. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once Every 3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-cycle Chemotherapy. Site Sub-Investigator
 - Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC. *J Thorac Oncol*. 2020 Feb;15(2):190-202. doi: 10.1016/j.jtho.2019.10.005. Epub 2019 Oct 16. PMID: 31629060.
 16. A multi-center, randomized, double blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int 1risk) and transfusional iron overload (TELESTO, NCT00940602) Site Sub-Investigator
 - Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. *Ann Intern Med*. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24. PMID: 32203980.
 17. A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Neoadjuvant Anthracycline-based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple Negative Breast Cancer (BRE 293, ImPassion031, NCT03197935) Site Principal Investigator
 - Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet*. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20. PMID: 32966830.
 18. The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection (NCT03085888), Site Sub-Investigator
 - Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann Oncol*. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30. PMID: 33506766; PMCID: PMC8274402.
 19. A multicenter, double-blind, placebo-controlled, randomized phase III trial to compare efficacy and safety of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease (NCT03659136), Site Principal Investigator
 - Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G,

- Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. *Breast Cancer Res.* 2021 Jan 15;23(1):8. doi: 10.1186/s13058-020-01382-8. PMID: 33451345; PMCID: PMC7811234.
20. A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (METRIC, Celldex, BRE-231, NCT01997333) Site Principal Investigator
- Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Hawthorne T, Bagley RG, Halim AB, Turner CD, Yardley DA. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. *NPJ Breast Cancer.* 2021 May 20;7(1):57. doi: 10.1038/s41523-021-00244-6. PMID: 34016993; PMCID: PMC8137923.
21. Phase I-II trial of H3B-6545, an antagonist of estrogen receptor alpha, in locally advanced/metastatic ER +, HER2 - breast cancer (BRE 287, H3 Biomedicine, NCT03250676), Site Principal Investigator
- Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Dees EC, Jones RH, Haley BB, Armstrong AC, Cohen AL, Munster PN, Wright GLS, Kayali F, Korpall Manav, Xiao JA, Long J, Destenaves B, Gao L, Gualberto A, Juric D, Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. *J Clin Oncol* 39, no. 15_suppl (May 20, 2021) 1018-1018
 - Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Dees EC, Jones RH, Haley BB, Armstrong AC, Cohen AL, Munster PN, Wright GLS, Kayali F, Korpall, Yu L, Cantagallo L, Destenaves B, Zhang Z, Gao L, Pipas MJ, Sahmouud T, Gualberto A, Juric D, Abstract PD8-06: Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. *Cancer Res* 15 February 2021; 81 (4_Supplement): PD8-06. <https://doi.org/10.1158/1538-7445.SABCS20-PD8-06> (Poster Spotlight Session, San Antonio Breast Cancer Symposium 2021)
22. A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole (RIBECCA, Novartis, NCT03096847), Principal Investigator
- Mattea Reinisch, Arndt Nusch, Thomas Decker, Andreas Hartkopf, Bernhard J Heinrich, Christian M Kurbacher, Roswitha Fuchs, Hans Tesch, Petra Krabisch, Sara Y Brucker, Tanja Fehm, Wolfgang Janni, Sherko Kuemmel, Diana Lüftner, Andreas Schneeweiss, Martin Schuler, Claudia Voges, Joerg Schubert, Peter A Fasching; Abstract PS10-31: Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results. *Cancer Res* 15 February 2021; 81 (4_Supplement): PS10-31. <https://doi.org/10.1158/1538-7445.SABCS20-PS10-31>
 - Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Gjerga E, Hennig S, Schaper S, Na

- IK, Keller U, Brucker S, Decker T, Fasching P, Fehm T, Janni W, Kümmel S, Schneeweiss A, Schuler M, Lüftner D, Busse A. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. *Eur J Cancer*. 2022 Feb;162:45-55. doi: 10.1016/j.ejca.2021.11.025. Epub 2021 Dec 23. PMID: 34953442.
23. TRINITY-1: A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with ER+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor: Triplet with Ribociclib, AfNitor® and AI posT CDK 4/6 Inhibitor (Novartis, BRE-279, NCT 02732119), Site Principal Investigator
 - Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha DS, Moulder S; Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITY-1). *Clin Cancer Res* 1 August 2021; 27 (15): 4177–4185.
 24. The impact of HER2 heterogeneity on the treatment of early-stage HER2-positive breast cancer: a phase II study of T-DM1 in combination with Pertuzumab in the preoperative setting. (BRE 263, NCT02326974), Principal Investigator
 - Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. *Cancer Discov*. 2021 Oct;11(10):2474-2487. doi: 10.1158/2159-8290.CD-20-1557. Epub 2021 May 3. PMID: 33941592; PMCID: PMC8598376.
 25. A Phase Ib, Open-Label, Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with: Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Doxorubicin with Cyclophosphamide in HER2-Negative Breast Cancer (BRE261, NCT02605915), Site Principal Investigator.
 - Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. *Clin Breast Cancer*. 2021 Dec;21(6):539-551. doi: 10.1016/j.clbc.2021.04.011. Epub 2021 May 15. PMID: 34154926.
 26. A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast02, NCT03523585), Site Principal Investigator
 - André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Royle R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a

- randomised, open-label, multicentre, phase 3 trial. *Lancet*. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. PMID: 37086745.
27. A phase III, trial of ribociclib w/endocrine therapy as an adjuvant treatment in HR +, HER2-early breast cancer (NCT03701334, NATALEE, BRE 322, Novartis), Site Principal Investigator
 - Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukiela-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia A, Im SA, Ruiz-Borrego M, Loi A, Xu B, Hurvitz S, Barrios B, Untch M, Moroos R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G; Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. *N Engl J Med* 2024; 390:1080-1091 DOI: 10.1056/NEJMoa2305488
 28. A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL; NCT04109066; BRE 345, Bristol-Myers Squibb), Site Principal Investigator
 - Loi S, Salgado R, Curigliano G, Romero Díaz RI, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suárez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu JQ, Pusztai L, McArthur H. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. *Nat Med*. 2025 Feb;31(2):433-441. doi: 10.1038/s41591-024-03414-8. Epub 2025 Jan 21. PMID: 39838118; PMCID: PMC11835735.
 29. Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02; NCT03975647; BRE 343; Seattle Genetics), Site Principal Investigator
 - Hurvitz, Sara. GS01-10 HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer. Presented at San Antonio Breast Cancer Symposium 2023 General Session 1 (GS01-10)
 30. A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications (NCT04024436, FOENIX-MBC2, BRE336, Taiho), Site Principal Investigator
 - Komal L. Jhaveri, Melissa K. Accordini, Philippe L. Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E. Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C. Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E. Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L. Schutzman, Dejan Juric Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. *JCO* 0, JCO.24.00110 DOI:10.1200/JCO.24.00110
 31. A Randomized, Multicenter, Open-Label, Two-Arm Phase II Neoadjuvant Study Evaluating the Efficacy, Safety and Pharmacokinetics of GDC-9545 plus palbociclib compared with

anastrozole plus palbociclib for postmenopausal women with Estrogen-Receptor Positive and Her2 Negative untreated Early Breast Cancer (BRE 357, NCT04436744; Hoffman-Roche), Principal Investigator

- Peter A. Fasching et al. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.. JCO 40, 589-589(2022). DOI:10.1200/JCO.2022.40.16_suppl.589
32. Randomized Phase III Trial Evaluating The Role of Weight Loss In Adjuvant Treatment Of Overweight And Obese Woman With Early Breast Cancer (Alliance: A011401, BWEL Study; NCT02750826) Site Sub- Investigator
- Jennifer A. Ligibel et al. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.. JCO 41, 12001-12001(2023). DOI:10.1200/JCO.2023.41.16_suppl.12001
33. LS-P-Destiny07—A Phase 1b/2 Multicenter, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07), Principal Investigator
- Andre F et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.. J Clin Oncol 42, 1009-1009(2024). DOI:10.1200/JCO.2024.42.16_suppl.1009
 - André, F. et al Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07; ESMO Open, Volume 10, 104163
34. LS-P-EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers, (Lilly, EMBER 1, NCT04188548) Site Sub- Investigator
- Komal L. Jhaveri et al. Imlunestrant, an Oral Selective Estrogen Receptor Degradar, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase 1a/1b EMBER Study. JCO 0, JCO.23.02733, DOI:10.1200/JCO.23.02733

PUBLICATIONS IN SUBMISSION

35. Louie AD, Bansal R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, El-Deiry WS, Dizon DS, **Graff SL**. Genomic characterization of breast cancer by metastatic site and variable co-expression of genomic mutations on survival: the impact of CDH1 and PIK3CA. *In submission*.
36. Meza KS, Eteshola EOU, Seymour K, Rodriguez B, **Graff SL**, Smith N, Elliott A, Holder SL. PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis. *In Submission*
37. Trapani D, Deshmukh SK, Samec T, Wu S, Xiu J, Walker P, Advani P, Spanheimer P, Lin NU, Curigliano G, **Graff SL**, Sledge GW, Tolaney SM, Leone JP, Influence of sex in the molecular, immunological and survival differences of breast cancer: a distinct disease in men. *In Submission*.

38. Jones S, Falchook G, **Graff SL**, Arrowsmith E, Kilari D, Gersten TA, Hussein M, Percent I, Burris HA. A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations. *In Submission*.
39. Narvaez D, Parkinson GT, **Graff SL**. Metronomic capecitabine plus aromatase inhibitor as initial therapy in Hormone Receptor-positive Human Epidermal Growth Factor Receptor 2-negative metastatic breast cancer: a low-cost and easily implementable option. *Invited Editorial Commentary, In Submission*
40. Knutson KL, Abu-Fares H, Block MS, Norton N, Erskine CL, Cogen D, Assad H, **Graff SL**, Hamilton EP, Han HS, McIntyre KJ, Nassar A, Sparano JA, Tiersten A, Tkaczuk KH, Ward PJ, Wilson G, Garrett G, Kenney RT, Sharma PA. A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer. *In Submission*.
41. Wang Y, Hacking S, **Graff SL**, Cheng L, L Liu. Genomic and Clinicopathological Characteristics of Low Oncotype DX Score Breast Cancers with Subsequent Metastasis. *In Submission*.
42. Aristei C, Curigliano G, Barrios C, Battisti NML, Cheung KL, Chia S, **Graff SL**, Hartmann OJ, Rubio I, Santini D, Sardanelli F; Senkus E; van Dam P, Walker M, Wu J. Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization, *In Submission*.
43. Steckler A, Raker CA, Sauerbrun-Cutler MT, Graff SL, Dizon DS, Duffy C. Counseling and Use of Surrogacy Among Cancer Survivors (CUSACS), *In Submission*.

ABSTRACTS

Includes abstracts not otherwise published or presented as part of other ongoing work; published projects have been removed

1. Huang, CH, **Graff SL**. Madan R, Kelly K., Insulin Growth Factors Receptor – 1 Expression in Small Cell Lung Cancer. *J Clin Oncol* 2010; 28(15S):e21098.
2. **Graff SL**, Wisner P, Shay-Zapfen G, Logan M, Moorman D. The value of breast cancer survivorship care plans: Results from a community survey. American Society of Clinical Oncology Annual meeting, Abstract #e22125, June 2018.
3. Prochaska, LH, Godwin AK, Kimler BF, **Graff SL**, et al. Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer. San Antonio Breast Cancer Symposium, December 2016. Abstract P5-16-02.
4. Hamilton EP, Petit T, Pistilli B, Goncalves A, Ferreira AA, Dalenc F, Cardoso F, Mita MM, Dezentjé VO, Manso LM, **Graff SL**, Bidard FC, Aftimos PG, Escrivá S, Afonso N, Wasserman E, Bol K, Stalbovskaya V, Vliet A, Bachelo T. Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. *J Clin Oncol* 38: 2020 (suppl; abstr 3093)
5. Louie AD, Chudasama R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, Obeid E, El-Deiry WS, Dizon D, **Graff SL**. Mutational landscape and immune infiltration of breast cancer metastases to gynecologic and other organs, Abstract 451, Spotlight Poster-Discussion Session 6: Genomic and Genetic Analysis on Metastases. 2021 San Antonio Breast Cancer Symposium
6. El-Deiry WS, Arnoff T, Sahin I, Khatri I, Lou E, Liu SV, Borghaei H, Plimack E, Subbiah V,

- Khan H, Carneiro B, Safran H, **Graff SL**, Dizon DS, Heath E, Wong E, George A, Hahn M, Chang WI, Raugi A, DeSousa A, Abbas A, Azzoli C, Demeure M, Marshall J, Lenz HJ, Doebele RC, Abraham J, Kurzrock R, Xiu J. A Pancancer analysis of impact of MDM2/MDM4 (MDMX) on immune checkpoint blockade (ICB). ASCO Annual Meeting 2022, Poster Presentation, Developmental Therapeutics—Immunotherapy June 5, 2022, #2630
7. Bustos MA, Yin J, Brodskiy P, Kang I, **Graff SL**, Sammons S, Dawar R, Spetzler D, Hoon DSB; Association of Interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC) patients with BRCA1/2 mutations. ASCO Annual Meeting 2022, Poster Presentation in Breast Cancer- Metastatic, Monday, June 6, 2022, #1030
 8. Hensing WL, Xiu J, **Graff SL**, Kang I, Torres ER, Heeke AL, Davis A, Bagegni N, Clifton K, Bose R, Ma C, Ademuyiwa FO. Prevalence and Prognosis of ER-loss in advanced invasive lobular carcinomas. San Antonio Breast Cancer Symposium, Prognostic and Predictive Factors, P3-05-08. December 7, 2022.
 9. Louie AD, Chudasama R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, Obeid E, El-Deiry WS, Dizon D, **Graff SL**. Genomic characterization of breast cancer metastases reveals differences in rates of PIK3CA mutation across metastatic sites and worse survival in patients with concurrent CDH1 mutation treated with PI3K inhibitor. Society of Surgical Oncology Annual Meeting, March 2023. *Accepted for Oral Presentation*.
 10. El-Deiry WS, **Graff SL**, Azzoli CG, Dizon DS, Fenton MA, Sikov WM, Safran HP, Khan H, Khurshid H, Schumacher A, Zhou L, Zhao S, Seyhan AA, Roxanne Wood R, Winer AA, Monden A, Calleja EM, Ross EA. BrUOG 387: Phase Ib investigator-initiated trial of an HSP90i combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb) deficiency (IND163592; NCT05655598). Poster Presentation, Clinical Trials in Progress, American Society of Clinical Oncology Annual Meeting 2023
 11. **Graff SL**, Elliott A, Mahtani RL, Tan AR Nabhan C, Holder SL, An Analysis of Proviral Insertion Site of Moloney Murine Leukemia Virus 1 Kinase Expression (PIM1) and Clinical Outcomes in Advanced Breast Cancer (ABC). *Poster Presentation*, European Society of Medical Oncology Congress 2023
 12. Haddad, SA, **Graff SL**, Wang Y, Taneja C, Leonard K, Fenton MA. Safety and Efficacy of KEYNOTE-522 in combination with anti-retroviral therapy in a patient with HIV and triple-negative breast cancer. Clinical Case Studies, 2023 San Antonio Breast Cancer Symposium 2023. *Poster Presentation*
 13. Loi S, Johnston S, Arteaga C, **Graff SL (presenting author)**, Chandarlapaty S, Goetz MP, Desmedt C, Reis-Filho JS, Sasano H, Rodrik-Outmezguine V, Sireci A, Sandoval C, Won H, Liu D, Litchfield LM, Turner N. “Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer” *accepted for Poster Spotlight Discussion*, “Prognostic and predictive uses of cell free DNA,” Wednesday, December 6, 2023, San Antonio Breast Cancer Symposium 2023
 14. Turner N, Reis-Filho JS, Goetz MP, Desmedt C, Chandarlapaty S, Sasano H, Arteaga CL, Loi S, **Graff SL**, Liu D, Rodrik-Outmezguine V, Sireci A, Rubenstein CS, Won H, Litchfield LM, Munoz M, Johnston S. Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial. *Oral Presentation*, General Session 3 on Friday, December 8, 2023, San Antonio Breast Cancer Symposium.

15. Trapani D, Deshmukh SK, Wu S, Xiu J, Walker P, Advani P, Lin NU, Curigliano G, **Graff SL**, Nabhan C, Sledge GW, Tolaney SM, Leone JP. Molecular and immunological landscape of sex-based differences in breast cancer: a distinct disease in men. *Poster Spotlight Presentation*, San Antonio Breast Cancer Symposium December 7, 2023.
16. Advani P, Deshmukh SK, Wu S, Andring J, Xiu J, Farrell A, Leone JP, Priya Jayachandran P, **Graff SL**, Oberley M, Sledge GW, Chanan-Khan A. Comprehensive Molecular and Immunological Characterization of Invasive Ductal Triple-Negative Breast Cancer. *Poster Presentation*, San Antonio Breast Cancer Symposium December 7, 2023.
17. Advani P, Deshmukh SK, Wu S, Andring J, Xiu J, Farrell A, Trapani D, Torres ER, Graff SL, Radovich M, Sledge GW, Chanan-Khan A. Comprehensive Characterization of BCL2 Family Genes in Metaplastic Triple Negative Breast Cancer. *Poster Presentation*, San Antonio Breast Cancer Symposium December 7, 2023.
18. Chang A, Singh K, **Graff SL**, Wang L, Yakirevich E, Wang Y. Is Oncotype DX Helpful in Clinical Decision Making for Invasive Micropapillary Carcinoma? *Poster Presentation*. United States and Canadian Academy of Pathology 2024 Annual Meeting
19. Holder SL, Lagos G, Carneiro B, Mega A, DeSouza A, McKay RR, Elliott A, Nabhan C, **Graff SL**. An analysis of Proviral Insertion Site of Moloney Murine Leukemia Virus, PIM1, kinase expression and clinical outcomes in renal cell carcinoma. *American Association for Cancer Research 2024 Annual Meeting*
20. **Graff SL**, Schmid P, Cristofanilli M, Cescon DW, Hovey T, Tse K, Vukovic P, O'Shaughnessy J. TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab versus Chemotherapy (CT) plus Pembrolizumab in Patients (pts) with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC) Miami Breast Cancer Conference (MBCC) 2024. March 7–10, 2024; Miami, FL, USA; Trials in Progress Abstract, Poster Presentation.
21. Advani P, Deshmukh SK, Wu S, Andring J, Xiu J, Leone JP, Jayachandran P, **Graff SL**, Oberley M, Sledge GW, Chanan-Khan A. Comprehensive Molecular and Immune Profiling of Triple Negative Invasive Lobular Carcinoma. *Poster Presentation, American Association for Cancer Research 2024 Annual Meeting*
22. Meza KS, Seymour K, **Graff SL**, Nabhan C, Elliott A, Holder SL. IL-6 and PIM1 expression in renal cell carcinoma. 2024 ASCO Genitourinary Cancers Symposium, Poster Session, J Clin Oncol 42, 2024 (suppl 4; abstr 470) DOI: 10.1200/JCO.2024.42.4_suppl.470
23. Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, **Graff SL**, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab versus Chemotherapy (CT) plus Pembrolizumab in Patients (pts) with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC) *Trials in Progress Encore Poster*, European Society of Clinical Oncology Breast Cancer Congress 2024
24. Desmedt C, Turner N, Johnston S, Arteaga CL, Sasano H, **Graff SL**, Loi S, Goetz MP, Liu D, Rodrik-Outmezguine V, Sireci A, Sandoval C, Won H, Litchfield LM, Munoz M, Chandarlapaty S. Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE, *Mini-Oral Presentation*, European Society of Clinical Oncology Breast Cancer Congress 2024
25. Manogna D, Wu S, Deshmukh SK, Xiu J, Ehsani S, Gopalakrishnan R, Sandoval-Leon A, Ueno N, Sammons S. Sledge GW, **Graff SL**. “Genomic and Tumor Microenvironment

- Dynamics of Brain Metastases in Breast Cancer.” *Mini-Oral Abstract Session*, American Society of Clinical Oncology Annual Meeting 2024
26. Bakow BR, Krause H, Elliott A, Soff GA, Trabolsi A, Antonarakis E, Oberley M, **Graff SL**. “The Prevalence of Sick Cell Phenotype and its Association with Clinical Outcomes in Patients with Solid Malignancies.” *Poster Presentation*, American Society of Clinical Oncology Annual Meeting 2024
 27. Loi S, Johnston S, Arteaga C, **Graff SL**, Chandarlapaty S, Goetz MP, Desmedt C, Sasano H, Liu D, Rodrik-Outmezguine V, Diereci A, Sandoval C, Won H, Litchfield LM, Turner N. “Prognostic utility of ctDNA dynamics in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).” *Oral Presentation*, American Society of Clinical Oncology Annual Meeting 2024
 28. Parkinson G, Lustberg M, Nazari SS, Elliott A, Sledge G, Jeselsohn R, Hsu E, Sobol RC, Sandoval AC, Gopalakrishnan R, Makhoul S, Nye L, Kurian AW, Lynce F, **Graff SL**. Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing, *Mini Oral Presentation*, European Society of Medical Oncology Congress 2024
 29. Tolaney SM, Cortes J, Hamilton E, Iwata H, Park YH, Tripathy D, Barroso-Sousa R, Curigliano G, Harbeck N, Rugo HS, Modi SM, **Graff SL**, Barrios C, Martmut K, Pistilli B, Aftimos P, Saji S, Koutras, Chakrabarti D, Bhatt K, Cai G, Wang X, Hurvitz S. EmpowHER 303: A phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab with chemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan. *Accepted for Poster Presentation*, San Antonio Breast Cancer Symposium 2024
 30. Mistry H, Fenton MA, Taneja C, MacKenzie A, Wang L, **Graff SL**. The Differential Diagnosis of a Large Breast Mass in a Young Woman” *Accepted for Poster Presentation*, San Antonio Breast Cancer Symposium 2024
 31. Wander S, Kalinsky K, Jeselsohn R, Bianchini G, Hamilton E, Martin M, Hurvitz S, Park KH, Sammons S, Kaufman P, Demirci U, Layman R, Knoderer H, Won H, Zhou Y, Ravenberg E, Sandoval C, Nguyen B, Litchfield L, **Graff SL**. Genomic profiling of ctDNA and association with efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy. *Accepted for Poster Presentation*, San Antonio Breast Cancer Symposium 2024; (*Encore presentation at Miami Breast Cancer Symposium, 2025*)
 32. Ghandali M, Srinivasan P, Wong E, Sobol RW, Zhou L, Carneiro B, **Graff SL**, El-Deiry SE. Tumor treating fields (TTF) shows efficacy in triple negative breast cancer (TNBC) cells and synergizes with PARP inhibitor Talazoparib. *Poster*, American Association for Cancer Research 2024 Annual Meeting
 33. Advani P, Deshmukh SK, Wu S, Xiu J, Leone JP, Jayachandran P, Oberley M, Lustberg M, **Graff SL**, Sledge GW, Chanan-Khan A. Molecular and Immune Landscape of Metaplastic Triple Negative Breast Cancer Compared with Invasive Ductal Triple Negative Breast Cancer. *Spotlight Poster Presentation*, San Antonio Breast Cancer Symposium 2024
 34. Trapani D, Deshmukh SK, Wu S, Xiu J, Jayachandran P, Lin NU, Curigliano G, Radovich M, Lustberg M, **Graff SL**, Sledge GW, Tolaney SM, Leone JP. Molecular and immunological characterization of HER2-low, HER2 ultra-low, and HER2-null male breast cancer. *Poster 3-01-25*, San Antonio Breast Cancer Symposium 2024
 35. Trapani D, Deshmukh SK, Wu S, Xiu J, Jayachandran P, Lin NU, Curigliano G, Spanheimer P, Radovich M, **Graff SL**, Lustberg M, Sledge GW, Tolaney SM, Leone JP. Prognostic

- implications of oncogenetic pathway alterations in advanced male breast cancer. *Poster I-01-16*, San Antonio Breast Cancer Symposium 2024
36. Trapani D, Deshmukh SK, Wu S, Xiu J, Advani P, Lin NU, Curigliano G, Flood W, **Graff SL**, Lustberg M, Spanheimer P, Sledge GW, Tolaney SM, Leone JP. Prognostic implications of oncogenetic pathway alterations in advanced male breast cancer, *Poster P1 05 21*, San Antonio Breast Cancer Symposium 2024
 37. Fasching PA, Barrios CH, Lim E, Graff SL, Chia S, Frenel JS, Im SA, Huang CS, Ring A, Nowecki Z, Liu Q, Akdere M, Sarate JP, Hu H, Pantoja K, O'Shaughnessy JA, Prognostic variables for risk of recurrence (ROR) in patients (pts) with HR+/HER2- early breast cancer (EBC) using data from the NATALEE trial: A machine learning (ML) model-based analysis, ePoster, St. Gallen's Early Breast Cancer Consensus Conference 2025
 38. Wander S, Kalinsky K, Jeselsohn R, Bianchini G, Hamilton E, Martin M, Hurvitz S, Park KH, Sammons S, Kaufman P, Demirci U, **Graff SL**, Layman R, Knoderer H, Won H, Zhou Y, Ravenberg E, Sandoval C, Nguyen B, Litchfield L, Baseline ctDNA and methylation status as predictors of treatment benefit in the Phase 3 postMONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients. European Society of Medical Oncology: *Breast Cancer 2025, Mini Oral Presentation*
 39. Nsuabayi C, Rehnquist MK, Sadetsky N, Sjekloca N, Lambert A, Hoge C, Dasgupta A, **Graff SL**. Do Patients and Physicians Report Symptoms and Side Effects Similarly? Examining Reporting Gaps in HR+/HER2- mBC: Using Quantitative PRO Instruments in Patients Across EU5 and the US. European Society of Medical Oncology: *Breast Cancer 2025, Poster Presentation*
 40. **Graff SL**, Cardosa F, Rugo HS, Brezden-Masley C, Werutsky G, Tripathy D, O'Shaughnessy JA, Ma C, Danso M, Lu Y, Basaran G, Campone M, De Laurentiis M, Cortes J, Worthy V, Gao M, Musel B, Ye F, Pantoja K, Fasching PA. Adjuvant WIDER: A phase IIb trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to clinical practice patient (pt) population with HR+/HER2- early breast cancer (EBC), Poster Presentation—Breast Cancer—Local/Regional/Adjuvant, June 2 2025 Poster #209A Abstract TPS617, Trial in Progress, American Society of Clinical Oncology Annual Meeting 2025
 41. Deshmukh SK, Wu S, Xiu J, Ernstoff MS, Hong CC, Yao S, Kalinski P, Leone JP, Chumsri S, **Graff SL**, Lustberg M, Sledge GW, Kalinsky K, Gandhi S. Molecular and Immune Characterization of Adrenergic Stress-Signaling Receptor ADRB2 in Triple Negative Breast Cancer (TNBC). Poster Presentation, Breast Cancer—Metastatic, American Society of Clinical Oncology Annual Meeting 2025
 42. Kalinsky K, Reinisch M, Lu YS, Debled M, Xu B, Hart L, **Graff SL**, Liu Q, Untch M, Loi S, Sharma P, Sakalosh V, Gao M, Santarsiero L, Waters S, Islam S, Im SA. NATALEE by menopausal status, Oral Presentation—Breast Cancer, Early Stage/Local Therapy, American Society of Clinical Oncology Annual Meeting 2025
 43. Steckler A, Raker C, Sauerbrun-Cutler MT, **Graff SL**, Dizon DS, Duffy CM. Awareness of gestational surrogacy as an option to parenthood for women treated for cancer: A national survey, Poster Presentation, American Society of Clinical Oncology Annual Meeting 2025
 44. Steckler A, Raker C, Sauerbrun-Cutler MT, **Graff SL**, Dizon DS, Duffy CM. Inclusion of gestational surrogacy in oncologist-led fertility counseling at cancer diagnosis: A national survey. Poster Presentation, American Society of Clinical Oncology Annual Meeting 2025
 45. Bustos MA, Deshmukh SK, Samec T, Wu, S, Xiu J, Advani P, Jayachandran P, Mahtani RL, **Graff SL**, Lustberg M, Sledge GW, Hoon DSB. Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC). Poster Presentation, American Society of Clinical Oncology Annual Meeting 2025,

46. Rehnquist MK, **Graff SL**, Vidal G, Sadetsky N, Hoge C, Holdsworth E, Müller V, Tredan O. Integrating Mixed Methods and Actigraphy to Advance Understanding of Adverse Events in Metastatic Breast Cancer: A Multi-Country Study, *Accepted for Poster Presentation*, International Society for Pharmacoepidemiology 2025, August 2025, Washington DC

ABSTRACTS IN SUBMISSION

1. Travaline C, Plagens RN, Elliott A, Sledge G, **Graff SL**, Lustberg M, Vasekar M. Outcomes in PIK3CA-mutated breast cancer patients treated with metformin. *In Submission*, San Antonio Breast Cancer Symposium 2025

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

1. “An Invitation to be Quiet No Longer,” **Graff, Stephanie**. ASCO Post, published online September 25, 2018. <http://www.ascopost.com/issues/september-25-2018/an-invitation-to-be-quiet-no-longer/>
2. “Gender Equity” **Graff, Stephanie**. ASCO Post, published online August 10, 2019. <https://www.ascopost.com/issues/august-10-2019/gender-equity/>
3. “Fostering a Culture of gender-based respect and inclusion in oncology” Duma N, Chapman C, **Graff SL**, Prowell TM, Knoll MA. Guest Editorial, The Cancer Letter. June 5, 2020. https://cancerletter.com/articles/20200605_7/
4. “The Ocean in Which We Float: Harassment in oncology is pervasive—just look at the data.” Guest Editorial, The Cancer Letter. June 11, 2021. **Graff SL**, Subbiah I, Markham MJ, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R. https://cancerletter.com/guest-editorial/20210611_1/
5. “Exercise Is Easy Prescription for Patients Concerned About Potential Cognitive Effects of Chemotherapy.” **Graff, Stephanie**. The Reading Room with MedPage Today and ASCO. Published Online October 5, 2021, at <https://www.medpagetoday.com/reading-room/asco/breast-cancer/94852>
6. “Sexual and Gender-Based Harassment in Oncology: It’s Not Just Time for Society to Heal—It’s Time for Us to Change.” Morgan, G, Choueiri TK, Dizon DS, Duma N, **Graff S**, Lewis M, Markham MJ. ASCO Daily News. Published Online October 6, 2021, at <https://dailynews.ascopubs.org/doi/10.1200/ADN.21.200722/full/#.YV4EHPbSb5c.twitter>
7. “Young, Empowered, and Strong -- Young Women with Breast Cancer Engage With Digital Health to Improve Sensitive Care Needs.” **Graff, Stephanie**. The Reading Room with MedPage Today and ASCO. Published Online April 5, 2022, at <https://www.medpagetoday.com/reading-room/asco/breast-cancer/96306>
8. “Prospective Surveillance for Breast Cancer-Related Arm Lymphedema.” **Graff, Stephanie**. The Reading Room with MedPage Today and ASCO. Published Online April 5, 2022, at <https://www.medpagetoday.com/reading-room/asco/breast-cancer/98038>
9. Loprinzi, C, Accordini M, Bandla A, **Graff S**. “Development of the Chemotherapy-Induced Peripheral Neuropathy Cyrocompression Device” Scalp Cooling Summit: The White Papers, May 5, 2022. Available online for download at <https://scalpcoolingsummit.com/keynote-discussions/chemotherapy-induced-peripheral-neuropathy/>
10. “What Hodgkin Lymphoma Survivors Should Know About Mantle Radiation and Breast Cancer Risk” Dibble EH, **Graff SL**, Graves TA, Miller CJ. Cancer.Net, American Society

of Clinical Oncology, June 14 2022. <https://www.cancer.net/blog/2022-06/what-hodgkin-lymphoma-survivors-should-know-about-mantle-radiation-and-breast-cancer-risk>

11. **Graff SL**, Bhavé MA, Sharifi M, Fasching PA. Considering Adjuvant CDK4/6 Inhibitors: MonarchE and NATALEE in Clinical Practice, *ASCO Daily News*, Published online 17 AUG 2023 <https://dailynews.ascopubs.org/doi/considering-adjuvant-cdk4-6-inhibitors-monarche-and-natalee-clinical-practice>

NON-PEER-REVIEWED: DIGITAL & PRINT MEDIA

1. “Scared of clinical trials? 7 reasons not to be.” **Graff, Stephanie**. KevinMD.com. Published online July 2, 2017. DOI: <https://www.kevinmd.com/blog/2017/07/scared-clinical-trials-7-reasons-not.html> Reprinted on the Sarah Cannon Cancer Blog and by Physician’s Weekly.
2. “Where physician and mother meet,” **Graff, Stephanie**. ASCO Connection. Published online June 13, 2017 DOI: <https://connection.asco.org/blogs/where-physician-and-mother-meet> Reprinted in “Best of ASCO Connection Blogs”, June 2018.
3. “The only perfect cancer statistic is an imperfect one”, **Graff, Stephanie**. KevinMD.com. published online May 30, 2017, DOI: <http://www.kevinmd.com/blog/2017/05/perfect-cancer-statistic-imperfect-one.html>
4. “This October, share the message of early breast cancer detection.” **Graff, Stephanie**. KevinMD.com. published online September 19, 2017. DOI: <http://www.kevinmd.com/blog/2017/09/october-share-message-early-breast-cancer-detection.html>
5. “Takeaways from the Women in Oncology Strategic Planning Retreat” **Graff, Stephanie**. ASCO Connection. Published online September 21, 2017 DOI: <https://connection.asco.org/blogs/takeaways-women-oncology-strategic-planning-retreat>
6. “Being a Physician-Patient Is a Double Edge Sword” **Graff, S** with Shanahan, K. ASCO Connection, Published online May 21, 2018. DOI: <https://connection.asco.org/blogs/being-physician-patient-double-edged-sword>
7. “Conference High” **Graff S**. ASCO Connection, published online June 8, 2018. DOI: <https://connection.asco.org/blogs/conference-high>
8. “Everything I Needed to Know, I Learned in a Cancer Clinic”, **Graff, Stephanie**. ASCO Connection, published online July 23, 2018. <https://connection.asco.org/blogs/everything-i-needed-know-i-learned-cancer-clinic>, re-released on KevinMD July 29, 2018 <https://www.kevinmd.com/blog/2018/07/the-most-valuable-lessons-in-life-can-be-learned-in-oncology.html>
Awarded APEX Award for Publication Excellence, Social Media – Single Blog Post. Communications Concepts, 2019; Best of ASCO Connections Blogs 15th Anniversary Special Edition 2024 ASCO Annual Meeting
9. “The Blame Game: Cancer Is Not the Patient’s Fault,” **Graff, Stephanie**. ASCO Connection, published online February 11, 2019. <https://connection.asco.org/blogs/blame-game-cancer-not-patients-fault>
10. “Honor National Women Physicians Day with Self-Care” **Graff, Stephanie**. ASCO Connection, published online February 1, 2019. <https://connection.asco.org/blogs/honor-national-women-physicians-day-self-care>. Reprinted in “Best of ASCO Connection Blogs”, June 2019.
11. “Takeaways from American Society of Clinical Oncology 2021 (ASCO)”, **Graff, Stephanie**

- Dr Susan Love Foundation for Breast Cancer Research Blog. Published online July 6, 2021. <https://drsusanloveresearch.org/takeaways-from-american-society-of-clinical-oncology-2021/>
12. “Cannabis & Breast Cancer: Seeing Through the Weed”, **Graff, Stephanie** Dr Susan Love Foundation for Breast Cancer Research Blog. Published online August 1, 2021. <https://drsusanloveresearch.org/cannabis-breast-cancer-seeing-through-the-weeds-by-stephanie-l-graff-md-facp/>
 13. “October: A Love-Hate Season”, **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online October 15, 2021. <https://drsusanloveresearch.org/october-a-love-hate-season-by-stephanie-l-graff-md-facp/>
Awarded APEX Award for Publication Excellence, Social Media – Single Blog Post. Communications Concepts, 2022
 14. “Giving Makes a House a Home” Graff, Stephanie. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online November 15, 2021. <https://drsusanloveresearch.org/giving-makes-a-house-a-home-by-stephanie-l-graff-md-facp/>
 15. “Key Takeaways: San Antonio Breast Cancer Symposium 2021.” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online November 15, 2021. <https://drsusanloveresearch.org/key-takeaways-san-antonio-breast-cancer-symposium-2021-by-stephanie-l-graff-md-facp/>
 16. “Find the ‘Pull’: A Reader’s Guide to Managing Career Transitions. **Graff, Stephanie**. ASCO Daily News. Published online February 1, 2022, at <https://dailynews.ascopubs.org/doi/10.1200/ADN.22.200837/full/>
 17. “Cure & Celebrations”, **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online April 12, 2022 <https://drsusanloveresearch.org/cure-celebrations-by-stephanie-l-graff-md-facp/>
 18. “Expanding Family Leave About Equity, Health.” Dibble, EH and **Graff, SL**. Editorial, *Providence Journal*. May 10, 2022. Available online at https://providencejournal-ri.newsmemory.com/?publink=276cef39a_1348482
 19. “Destiny Breast” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online June 8, 2022 at <https://drsusanloveresearch.org/destiny-breast-by-dr-stephanie-l-graff-md-facp/>
 20. “The Shock of Breast Implant Associated Lymphoma” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online August 20, 2022 at <https://drsusanloveresearch.org/the-shock-of-breast-implant-associated-lymphoma-by-dr-stephanie-l-graff-md-facp/>
 21. “The One with the Pie Crust” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online November 22, 2022. <https://drsusanloveresearch.org/the-one-with-the-pie-crust-by-dr-stephanie-graff/>
 22. “San Antonio Breast Cancer Symposium 2022” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online January 3, 2023 <https://drsusanloveresearch.org/what-makes-an-advocate-by-dr-stephanie-graff/>
 23. “What Makes an Advocate” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online March 1, 2023 <https://drsusanloveresearch.org/san-antonio-breast-cancer-symposium-2022-by-dr-stephanie-graff/>
 24. “Identifying and Addressing Implicit Bias in the Workplace,” *Journal of Oncology Navigation & Survivorship* 14(2):Feb 2023; Buffington, Mary based on the work of **Graff, Stephanie**. Published online February 20, 2023 at <https://jones->

- online.com/issues/2023/february-2023-vol-14-no-2?view=article&artid=4816:identifying-and-addressing-implicit-bias-in-the-workplace
25. “Bring On the Babies: The POSITIVE Trial, Pregnancy, and Breast Cancer” **Graff, Stephanie**. Dr. Susan Love Foundation for Breast Cancer Research Blog. Published online July 4, 2023 at <https://drsusanloveresearch.org/bring-on-the-babies/>
 26. “Reforms Urged to Bridge Gender Gaps in Cancer Care.” Quoted as **Graff SL**. *Cancer Discov* 2023; <https://doi.org/10.1158/2159-8290.CD-NB2023-0072>
 27. Best Practices for Detecting ESR1 Mutations in Metastatic Breast Cancer. **Graff, Stephanie**. ReachMD. Published online December 2023. <https://reachmd.com/programs/project-oncology/best-practices-for-detecting-esr1-mutations-in-metastatic-breast-cancer/16207/>
 28. How “Dr. Susan Love’s Breast Book” has remained the “Bible” for women with breast cancer in 1990” **Graff, Stephanie**. Cancer History Project by *The Cancer Letter*. Published online March 29, 2024. Available at <https://cancerhistoryproject.com/article/how-dr-susan-loves-breast-book-has-remained-the-bible-for-women-with-breast-cancer-since-1990/>
 29. Community Focus: Breast Cancer & Clinical Trials. **Graff, Stephanie**. WPRI-12 FOX Providence, Live in Providence RI on July 9, 2024. Available online at <https://lnkd.in/d58fiYkh>
 30. Women Under 40 Are experiencing increased Rates of Breast Cancer. G. Wayne Miller, Nancy Kirsh. Ocean State Stories, The Pell Center, Salve Regina University. Published Online March 19, 2025 available at <https://oceanstatestories.org/women-under-40-are-experiencing-increased-rates-of-breast-cancer/>
 31. HemeOnc.org Weekly Content Update (March 31- April 6, 2025) Comment on PostMonarch trial. Published online April 7, 2025, available at [https://hemonc.org/wiki/Weekly_content_update#HemOnc.org_Weekly_Content_Update_\(March_31_-_April_6,_2025\)](https://hemonc.org/wiki/Weekly_content_update#HemOnc.org_Weekly_Content_Update_(March_31_-_April_6,_2025))
 32. “Unlocking the Potential of Immunotherapy in TNBC”, Breast Cancer Breakthroughs, Susan G. Komen Video

INVITED PRESENTATIONS

LOCAL

1. “Case Studies in Advanced Cardiac Life Support,” Expert Panel, St. Luke’s Hospital, May 21, 2008
2. “Lung Cancer”, University of Kansas Medical Center Core Curriculum, January 12, 2010.
3. “Breast Cancer Risk Reduction in the High-Risk Patient”, Research Medical Center Noon Conference, Kansas City, Missouri, September 2011
4. “Breast Health: Prevention & Risk Reduction”, Nursing education program, Research Medical Center, Kansas City, Missouri, October 21, 2011
5. “Simplifying Dense Breast Tissue & the Importance of Advanced Screening”, HCA Midwest Health Division Grand Rounds, Kansas City, MO, March 2021 (Virtual, COVID19)
6. “Conversations with the Authors Off Our Chests: A Candid Tour Through The World of Cancer,” panelist, Brown Cancer Center, Providence RI, November 2021
7. “Beyond Staging in Hormone Receptor Positive Breast Cancer: Genomics to Define Treatment & Prognosis” Brown Medicine Grand Rounds, Providence RI March 1, 2022
8. “Fostering Success in Research”, Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; May 19, 2022
9. “How to Navigate ASCO Annual Meeting” Hematology/Oncology Fellows Conference,

- Warren-Alpert School of Medicine, Brown University, Providence RI; May 19, 2022
10. “Metastatic Hormone Receptor Positive Breast Cancer”, Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; May 19, 2022
 11. “Life After Training: A Casual Evening with Faculty,” Panel Discussion, Hematology/Oncology Fellows, Warren-Alpert School of Medicine, Brown University, Providence RI; May 27, 2022
 12. “Redefining Breast Cancer,” Massachusetts General Hospital Multidisciplinary Breast Rounds, Boston, MA; May 31, 2022
 13. “The 2% of Breast Oncology You Need to Know,” Brown Internal Medicine Noon Conference, Rhode Island Hospital, Providence, RI; September 16, 2022
 14. “SABCS Updates” Hematology/Oncology Grand Rounds, Legorreta Cancer Center at Brown University, Providence RI, January 19, 2022
 15. “Breast Cancer State of the Union”, Translational Disease Working Groups Strategic Retreat, Legorreta Cancer Center at Brown University, Providence RI, February 18, 2023
 16. “Updates in Breast Oncology”, Translational Disease Working Group, Legorreta Cancer Center at Brown University, Providence RI, March 23, 2023
 17. “Advancing ADCs,” Cancer Therapeutics Program, Legorreta Cancer Center at Brown University, Providence RI, April 7, 2023
 18. “CIPN”, Oncology Advanced Practice Providers, Brown University Health Health Center Monthly Meeting, Providence, RI. April 2023
 19. “Hormone Receptor Positive Metastatic Breast Cancer,” Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; April 2023
 20. “CDK4/6 Inhibitors in Early-Stage Breast Cancer” Hem/Onc Grand Rounds, Legorreta Cancer Center at Brown University, Providence RI, January 11, 2024
 21. “Hormone Receptor Positive Metastatic Breast Cancer,” Hematology/Oncology Fellows Core Curriculum Series, Warren-Alpert School of Medicine, Brown University, Providence RI; April 11, 2024
 22. “Translational Science Principles: Breast Cancer TRDG Update” Translational Disease Working Groups Strategic Retreat, Legorreta Cancer Center at Brown University, Providence RI; May 24, 2024
 23. “SABCS 2024 Review: EMBER-3” Hem/Onc Grand Rounds, Legorreta Cancer Center at Brown University, Providence RI, January 9, 2025
 24. “Take Wing”, Comments, Hooding Ceremony, University of Missouri-Kansas City School of Medicine Commencement Ceremony, May 2025

REGIONAL

1. New Insights on Non-Hodgkin’s Lymphoma”, Current Trends in Leukemia, Lymphoma and Myeloma; Stower’s Institute for Medical Research, Kansas City, Missouri, February 5, 2011
2. Moderator, University of Kansas Cancer Center Lung Cancer Symposium, Kansas City, Kansas, March 3, 2012.
3. “State of the Art: Breast Cancer Update,” Kansas City Southwest Clinical Society 90th Annual Fall Clinical Conference, Overland Park, Kansas, November 3, 2012
4. Moderator, University of Kansas Cancer Center Lung Cancer & Head and Neck Cancer Symposium, Kansas City, Kansas, March 9, 2013
5. “Oncologic Emergencies,” Kansas City Southwest Clinical Society Current Management in Critical Care, Overland Park, Kansas, May 2, 2013

6. "Cancer In Kansas City." Served as expert panelist for live televised discussion on KCPT in conjunction with airing of Ken Burns' documentary "The Emperor of All Maladies." Kansas City, Missouri, April 2015.
7. "Genomics & Genetics: Breast Cancer in 2016". Innovations in Oncology Conference, Kansas City, Missouri. October 2016.
8. "Estrogen Receptor Positive Metastatic Breast Cancer", Break-out Sessions, Sarah Cannon Research Institute Annual Scientific Meeting, Nashville, Tennessee, March 4, 2017
9. "Breast Cancer Prevention and Diagnosis", Southwest Clinical Society Fall Clinical Conference, Overland Park, Kansas, October 5, 2017.
10. "AJCC 8th Edition: Where Staging & Genomics Meet", 2017 Bi-State Regional Education Meeting, Missouri State Tumor Registrars Association, **Keynote Address**, Riverside, Missouri, October 25, 2017.
11. "Metastatic Breast Cancer" OncLive State of Science Symposium, Kansas City, MO June 30, 2018 "If It's Broken, Don't Fix It: Targeting Cancer and DNA Repair," Break-out Sessions, Sarah Cannon Research Institute Annual Scientific Meeting, Nashville, Tennessee, March 10, 2018
12. "TailorX and Gene Expression in Modern Breast Cancer Care," Oklahoma Society of Clinical Oncology Best of ASCO Review, Oklahoma City, OK, September 15, 2018
13. "Escalation and De-escalation of Treatment in Early-Stage Hormone Receptor Positive Breast Cancer," OncLive State of Science Symposium, Nashville, TN, January 14, 2019
14. "Escalation and De-escalation of Treatment in Early-Stage Hormone Receptor Positive Breast Cancer," OncLive State of Science Symposium, Overland Park, KS, February 2, 2019
15. "Highlights in Breast Cancers: ASCO 2019," ASCO Direct™ Highlights: Kansas City, MO, June 2019
16. "Hormone receptor positive early-stage breast cancer" OncLive State of Science Symposium, Nashville, TN, January 2020.
17. *"Breast Cancer" Break-out Sessions, Sarah Cannon Research Institute Annual Scientific Meeting, Nashville, Tennessee, March 2020 (cancelled, COVID19)*
18. "Breast Cancer Screening and Risk Reduction: Management of the High-Risk Patient," Bixby Symposium, October 2020 (Virtual, COVID19)
19. "Living the State Motto" **Keynote Address**, American Cancer Society Cancer Action Network Breakfast, November 2021, Providence RI
20. "Breast Medical Oncology: Where Are We Now?," Not Your Grandma's Mammogram: An Update In Breast Health for 2022, Rhode Island Women's Health Initiative, Warren Alpert Medical School, May 25, 2022, Providence RI
21. "Alcohol & Breast Cancer—Intersections" Breas Cancer Translational Disease Group, Legorreta Cancer Center at Brown University, June 15, 2022, Providence, RI
22. "Research in Rhode Island" Panel Discussion, Moderator, 9th Annual Rhode Island Research Breakfast, American Cancer Society Cancer Action Network, 7 OCT 2022, Providence, RI
23. "Premenopausal Breast Cancer" & panel discussion, OncLive State of the Science Summit, Providence, RI, March 21, 2023 (Event Chair)
24. "ADCs: New Approvals & Emerging Directions" & panel discussion, OncLive State of the Science Summit, Providence, RI, March 21, 2023 (Event Chair)
25. "Case-based Roundtable in Breast Cancer," Dartmouth NH, September 27, 2023
26. "Disparities in Early Detection," Middlesex Health, Middletown CT, September 28, 2023
27. "Caring for the High-Risk Breast Cancer Patient into Adulthood" Consortium for New England Childhood Cancer Survivors (CONNECCS), Semi-Annual Meeting, Providence RI, May 8, 2024

28. “Gaps in Care & Policy Solutions Facing Rhode Island” Panel Debate, Annual Rhode Island Research Breakfast, American Cancer Society Cancer Action Network, 30 SEPT 2025, Providence, RI (*invited*)
29. “ctDNA in HR+ Early Breast Cancer”, Tufts Grand Rounds, Boston MA (*invited*)
30. “Team-Based Guide to Managing Targeted Therapies and their Toxicities” (*Invited*), Landmark Medical Center, Providence RI,

NATIONAL

1. “Community Breast Oncology” Panelist. United States Food and Drug Administration Mini-Symposium, Bethesda MD, September 2017.
2. “From Sequencing to Social Media: Modern Era Oncology.” Seminar Series, Genospace, Boston MA, April 24, 2019.
3. “Building Your Brand.” Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
4. “A Social Media Toolkit to Enhance Your Career,” Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
5. “Women’s Leadership in the Pandemic: Balancing Leading, Achieving, and Innovation,” West Virginia University Women in Science & Health Grand Rounds, West Virginia University School of Medicine, Morgantown, WV (Virtual, COVID19) February 11, 2021
6. “Emerging Biomarkers in Breast Cancer – Looking Beyond ER, PR, and HER2,” Panelist, Food & Drug Administration Oncology Center of Excellence Mini-Symposium, Bethesda MD, March 31, 2021 (Virtual, COVID19)
7. “Advocating for Patients: Overcoming Obstacles in Care,” followed by “Unanswered Questions in Navigation” expert panel, National Consortium of Breast Centers Annual Meeting, Las Vegas NV, April 2021 (Postponed from April 2020, Virtual, COVID19)
8. “Impact of Pathways Implementation,” National Consortium of Breast Centers Annual Meeting, Las Vegas NV, April 2021 (Postponed from April 2020, Virtual, COVID19)
9. “Communication & Collaboration with Referring Physicians,” National Consortium of Breast Centers Annual Meeting, Las Vegas NV, April 2021 (Postponed from April 2020, Virtual, COVID19)
10. “Leading During Challenging Times” ASCO COVID-19 Professional Development Roundtable, June 11, 2020 (Virtual, COVID19)
11. “ASCO Women in Oncology Open Forum: Gender Bias and Harassment in the Workplace” Panelist, American Society of Clinical Oncology webinar, Alexandria, VA (Virtual), June 2021
12. “Breast Cancer Update in Triple Negative and HER2 Breast Cancers”, & Masters Roundtable panelist, Evolving Treatments for the Oncology Practice. Nashville, TN, June 2021
13. “NRG Oncology Social Media Workshop,” NRG Oncology Virtual Summer Meeting, July 26, 2021
14. “Targeted Therapies in Metastatic Breast Cancer” and Panel Discussion, 2021 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes, Binaytara Foundation, Salt Lake City, UT, October 2021
15. “Advanced Breast Cancer”, Best of ASCO 2021 – Providence, Providence, RI, October 2021
16. “Careers in Breast Cancer” San Antonio Breast Cancer Symposium 2023 Satellite Meeting, with Caris Precision Oncology Alliance, December 2021
17. “Create Collaboration to Expand Drug Development Initiatives: A Principal Investigator’s Perspective” (Keynote Address), Early Phase Site Strategy Virtual Summit, January 18, 2022

18. “Triple Negative Breast Cancer Grand Rounds: Practical Guidance for the Community Oncologist”, Kootenai Clinic Cancer Services, Coeur d’Alene, ID, January 26, 2022
19. “Collaborating with Community Providers for Program Success”, High Risk Breast Cancer Pre-Course, National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2022
20. “Implicit Bias: Identifying & Addressing” (Plenary Lecture), National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2022
21. “Relationship Building in the Multi-disciplinary Model”, National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2022
22. “Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2” Grand Rounds, Ascension Macomb-Oakland Hospital, Warren MI, April 22, 2022
23. “Triple Negative Breast Cancer and the Role of ADCs,” Grand Rounds, Rush Medical Center Grand Rounds, Chicago IL (Virtual), April 29, 2022
24. “Triple Negative Breast Cancer”, Grand Rounds, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis IN (Virtual), May 20, 2022
25. “Best Practices in HER2+ Metastatic Breast Cancer: Optimizing Combination Therapies” with panel discussion, Oncology Meeting Innovations/DAVA, (Virtual), September 13, 2022
26. “Implicit Bias”. Academy of Oncology Nurse & Patient Navigators (AONN+) Annual Navigation and Survivorship Conference, New Orleans, LA, November 3, 2022
27. “How I Treat Refractory Metastatic HR+/HER2- Metastatic Breast Cancer,” ASCO Expert Answers, Digital Web CME Module, Recorded February 10, 2023
28. “Mutational Landscape of HER2-Low Metastatic Breast Cancer” and “Key Takeaways, SABCs 2022”, Caris Precision Oncology Breast Diseases Working Group Meeting, Phoenix AZ (Virtual), February 28, 2023
29. “Simply Said: Communicating the Complexity of High-Risk Care with Patients: A Role Play”, High-Risk Breast Cancer Pre Course, National Consortium of Breast Centers 2023 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
30. “We The People: Building a Democratic High-Risk Program,” High-Risk Breast Cancer Pre Course, National Consortium of Breast Centers 2023 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
31. “Beyond Buzzwords: Including Inclusivity & Micro-interventions to Microaggressions” (Plenary Lecture), National Consortium of Breast Centers 2023 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
32. “Disparities in Breast Cancer Care,” Panel Discussion, National Consortium of Breast Centers 2022 Annual Interdisciplinary Breast Cancer Conference, Las Vegas NV, March 2023
33. “Simone's Maxim for our Time” Panel Discussion, COVID-19 and Cancer Consortium 3rd Annual Retreat, Warren-Alpert Medical School Brown University, Providence RI, 31 MAR 2023
34. “Evolving Strategies in Hereditary Cancer 2023: Examining Equity and Implicit Bias in Cancer Care,” Myriad Genetics Oncology Continuing Education Series, April 7, 2023
35. “The Promise of Oral SERDS” & Panel discussion, OncLive Institutional Perspectives in Cancer, Emory Winship Cancer Institute, Atlanta GA (Virtual), April 18, 2023
36. “ESMO Breast 2023 Key Takeaways”, Caris Precision Oncology Alliance National Breast Meeting, (Virtual) May 23, 2023
37. **Graff SL**, Tolaney S, Hart L, Razavi P, Fasching PA, Janni W, Schwartzberg L, Lanoue B, Pathak P, Salas TR, Khakwani A, McDermott C, O’Shaughnessy J. Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients

- with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) early breast cancer (EBC): a US database analysis. Poster Presentation: Breast Cancer—Local/Regional/Adjuvant, American Society of Clinical Oncology Annual Meeting 2023, June 2023
38. **Graff SL**, Freeman E, Roach M, Wilson W, Stemland J, Chan B, Wochal P, Katz J, May SG. “Forging a Patient-Centered Collaborative Research Path: Unveiling Perspectives on Clinical Meaningfulness in Metastatic Breast Cancer with Clinicians, Patients, and Caregivers” *Poster Presentation*, 27 Oct 2023, American Society of Clinical Oncology Quality Care Symposium 2023, Boston MA.
 39. ASCO 2023 Breast Cancer Updates, Targeted Oncology and Oncology Brothers. June 2023, Virtual
 40. “Breast Cancer Highlights from ASCO 2023”, Caris Precision Oncology Alliance Breast Cancer Working Group Meeting, (Virtual) August 22, 2023
 41. “Breast Cancer”, Moderator, Best of ASCO 2023 Providence, Providence, RI, September 23, 2023
 42. “Breast Cancer Update” ASCO Direct, Cincinnati Cancer Advisors, Cincinnati OH, September 30, 2023
 43. “Moving Beyond the Binary Categorization of HER2 Status: Antibody-Drug Conjugate Therapy in Metastatic Breast Cancer,” teleECHO (Extension for Community Healthcare Outcomes), (Virtual) October 26, 2023
 44. “How I Manage Oligometastatic Disease”. Annual Savannah Symposium, Georgia Cancer Center. Savannah GA, October 27, 2023
 45. “Metastatic HER2+ Breast Cancer” JADPRO Live, Journal of the Advanced Practitioner in Oncology Annual Meeting, Orlando FL, November 11, 2023
 46. “Pivoting to New Paths – Charting a New Way Forward,” ASCO Professional Development Series for Women in Oncology, November 14, 2023, Virtual
 47. “Forging a Patient-Centered Collaborative Research Path: Insights & Discussion of Clinical Meaningfulness in Metastatic Breast Cancer with Clinicians, Patients, and Caregivers,” San Antonio Breast Cancer Symposium Satellite Symposium, December 6, 2023
 48. **Graff SL**, Freeman E, Roach M, Wilson R, Fairley R, Guallatte M, Stemland J, Chan B, Wochal P, Katz J, May-Slater S. Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making: Experiences and Perspectives of Patients, Caregivers, and Clinicians. *Poster Presentation*. 6 DEC 2023 2023 San Antonio Breast Cancer Symposium, San Antonio, TX
 49. **Graff SL**, Tolaney S, Hart L, Razavi P, Janni W, Schwartzberg L, Danyliv A, Payan JCM, Ferrusi I, Adhikary RR, O’Shaughnessy J. Invasive disease-free survival (iDFS) as a surrogate for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) early breast cancer (EBC): a real-world analysis. *Poster Presentation*. 2023 San Antonio Breast Cancer Symposium.
 50. “Hormone Receptor-Positive Breast Cancer,” Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology. Research to Practice, Virtual. January 11, 2024
 51. Breast Cancer Updates. 5th Annual Guthrie Virtual P.A.U.S.E. (Physicians and Advanced Practice Providers United in Substantive Education) Summit, Guthrie Clinic of Northern Pennsylvania and Central New York (Virtual), February 19, 2024
 52. “Getting the Support You Need for a High Risk Breast Program”, National Consortium of Breast Cancer 2024 Annual National Meeting, Las Vegas NV, March 2024
 53. “What To Do At Home: Medical Oncology” National Consortium of Breast Cancer 2024

Annual National Meeting, Las Vegas NV, March 2024

54. Fertility Preservation and Quality of Life in Premenopausal Patients With Breast Cancer, Ask The Experts Session (during ASCO Annual Meeting), Union League Club of Chicago, Chicago, IL, May 2024
55. “Getting the Story *Write*: Narrative Medicine to Hear, Heal and Help” American Society of Clinical Oncology Annual Meeting, Chicago IL, June 2024
56. “Hormone Receptor Positive Breast Cancer” 2024 Upstate New York Cancer Symposium with Wilmont Cancer Institute and Roswell Park Cancer Center, Rochester NY; June 2024
57. “The Digital Opinion Leader: Defining It and Collaborating Challenges” Roundtable, Collaboration for Outcomes using Social Media in Oncology (COSMO), September 19, 2024, Providence RI
58. “HER2+ Breast Cancer” Advancements in Oncology, San Antonio Breast Cancer Symposium Satellite Symposium, December 11, 2024, San Antonio, TX
59. “Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing” Caris Precision Oncology Alliance Quarterly Meeting, San Antonio Meeting, December 2024
60. Fertility Preservation and Quality of Life in Premenopausal Patients With Breast Cancer, Ask The Experts Session, San Antonio Breast Cancer Symposium Satellite Symposium 2024, San Antonio TX, December 2024
61. “Best of 2024: Systemic Therapy” National Consortium of Breast Centers 2025 Annual Meeting, March 2025, Las Vegas, NV
62. “There’s No Crying in Business Plans” Build It & They Will Come: A Leader’s Guide to Building Breast Programs Leadership Program. National Consortium of Breast Centers 2025 Annual Meeting, March 2025, Las Vegas, NV
63. “Farm to Table(t): A Story of Personal & Drug Development” E. Grey Diamond Take Wing Award Lecture, Grand Rounds, University of Missouri-Kansas City School of Medicine, May 2025, Kansas City, MO
64. “Understanding the Role of ESR1 Mutations in Metastatic Breast Cancer,” ASCO Annual Meeting Satellite Symposium, Chicago IL, May 30, 2025
65. “Emerging Molecular Tools in HR+ Early Breast Cancer” Medical College of Wisconsin Grand Rounds, Milwaukee, WI August 14, 2025
66. “Leveraging Molecular Tools to Guide Treatment Planning in HR+ Early Breast Cancer,” Perspectives on Breast Cancer, Medscape Live!, Washington DC, September 12, 2025
67. “Showcasing Innovation: The ACS NBCRT Risk Assessment Toolkit,” American Cancer Society National Breast Cancer Roundtable National Meeting, Washington DC, September 18, 2025
68. “Redefining Academic Success with Media, Boards, and Advocacy”, Power of Women In Medicine Summit, Chicago IL, September 19, 2025

INTERNATIONAL

1. “How Close Is Too Close: Navigating Difficult Situations” and panel discussion, session: When Cancer Hits Close to Home: Treating Colleagues and Loved Ones, American Society of Clinical Oncology Annual Meeting 2018, Chicago, IL, June 4, 2018
2. “How to Prepare Fellows for Transition to Private Practice” and panel discussion, session: Training Program Directors’ Breakfast, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 2, 2019

3. “Potential Pitfalls of Community Cancer Research,” and panel discussion, session: Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 2, 2019
4. “Mind the Gap”, Professional Development Poster Session Discussant, American Society of Clinical Oncology Annual Meeting, Chicago, IL (Virtual, COVID19), May 2020
5. “The Myth of Work Life Balance” Mexican Society of Oncology (Sociedad Mexicana de Oncología) International Oncology Congress, Mexico City, Mexico, October 2020 (Virtual, COVID19)
6. “Gene Expression Signatures: Personalizing Early-Stage Breast Cancer,” Breast Cancer in Young –Modern Approaches and Challenges Conferences, Georgian School of Oncology, Tbilisi, Georgia (Virtual/COVID19), June 2021
7. “Digital Advances in the Metastatic Breast Cancer Treatment Landscape” and Panel Discussion, Asian Pacific Oncology Summit (Virtual/COVID19), 5 OCT 2021
8. Precision Care: Taking Aim at Collateral Damage, A Pre-San Antonio Breast Cancer Symposium 2021 Webinar and Panel Discussion with the Dr. Susan Love Foundation for Breast Cancer Research, December 3, 2021 (Virtual/COVID-19)
9. “Development of CIPN Cyro-Compression Device”, (Keynote Discussion) Scalp Cooling Summit, May 5, 2022, Huddersfield, United Kingdom (Virtual, pre-recorded with live Q&A)
10. Technology-Enabled Clinical Trials Using Electronic Health Record-Derived Real-World Data: Opportunities and Limitations”, DIA 2022 Global Annual Meeting, Chicago IL, Jun 2022
11. “From the Panel to the Patient: Clinical Implications of Germline Testing for Breast Cancer,” Poster Discussant, Prevention, Risk Reduction, and Hereditary Cancer Session, 2022 American Society of Clinical Oncology Annual Meeting, Chicago IL, June 6, 2022
12. “Emerging Trends & Controversies Guiding Breast Cancer Research,” 3rd Annual OncoAlert Colloquium, January 23-28, 2023. Virtual. Available On Demand at <http://www.oncoalert360.com/the-oncoalert-colloquium-2022.html>
13. “Meet the Experts: Scalp Cooling and Cryotherapy: Latest Advancements to Address Chemotherapy-Induced Alopecia and Peripheral Neuropathy” Multinational Association of Supportive Care in Cancer (MASCC), Japanese Association of Supportive Care in Cancer (JASCC), and International Society of Oral Oncology (ISOO) 2023 Annual Meeting, Nara, Japan, June 23, 2023
14. “Multidisciplinary Perspectives in Breast Cancer”, The Multidisciplinary Perspectives in Breast Cancer, OncoAlert and Mirrors in Medicine, Brussels, Belgium, October 6, 2023
15. “One Size Does Not Fit All: Personalizing Endocrine Therapy Recommendations in Breast Cancer.” Multinational Association of Supportive Care in Cancer, Webinar/Virtual, November 30, 2023
16. “Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer” Poster *Spotlight Discussion*, “Prognostic and predictive uses of cell free DNA,” Wednesday, December 6, 2023, San Antonio Breast Cancer Symposium 2023
17. “Treatment post CDK 4/6 inhibitors” Session Moderator, San Antonio Breast Cancer Symposium® (SABCS) 2023, San Antonio TX
18. “HER2-Positive Metastatic Breast Cancer: The Year in Review 2023,” 4th Annual

- OncoAlert Colloquium in partnership with ASTRO/ESSO/MASCC/ESGO/SIOG, February 4-10, 2024. Virtual.
19. “Impact of Her2 Low on Survival in Patients Treated with Standard Therapies in Advanced Breast Cancer” Poster Presentation. **Graff SL** Bansal R, Adeyelu T, Elliott , Walker A, Bustos M, Rodriguez E, Accordini ML, Meisel J, Gatti-Mays M, Hsu E, Kaklamani V, Oberley M, Sledge G, Sammons SL. European Society of Clinical Oncology: Breast Congress 2023, Berlin Germany.
 20. “Breaking New Ground with CDK4/6 Inhibitors: Case-based Discussions on Treatment Decisions in HR+/HER2- Breast Cancer”, ESMO Breast Cancer, Berlin Germany, May16, 2024
 21. “Advanced Hormone Receptor Positive Breast Cancer” Kenya Society of Hematology & Oncology (KESHO), Nairobi, Kenya (virtual), October 10, 2024
 22. “A Day in the Life with CDK4/6 Inhibitors” Canadian Association of Medical Oncology (CAMO) Annual Scientific Meeting, Ottawa, Ontario, Canada, October 25, 2024
 23. “Emerging Role of ctDNA in early breast cancer management” Emirates Oncology, Abu Dhabi, United Arab Emirates, November 16, 2024
 24. “Adjuvant CDK4/6 Inhibitors in Early Breast Cancer Debate: Ribociclib” Emirates Oncology, Abu Dhabi, United Arab Emirates, November 17, 2024
 25. “Maximizing the options for the treatment of patients with hormone receptor positive, HER2 negative early breast cancer- a multidisciplinary approach” 8th Montreal Breast Cancer Symposium de Montreal en Cancer du Sein, Montreal, Quebec Canada, November 21, 2024
 26. “HER2-Positive Metastatic Breast Cancer: The Year in Review 2024,” 5th Annual OncoAlert Colloquium in partnership with ASTRO/ESSO/MASCC/ESGO/SIOG, January 17, 2025. Virtual
 27. Breaking New Grounds in HR+ HER2- Early Breast Cancer, Excellence in Oncology Care (EIOC) Journal Club, June 17, 2025, Dubai, United Arab Emirates

DIGITAL

1. “The Cattle Don’t Care” Journal of Clinical Oncology Cancer Stories: The Art of Oncology Podcast Series with Lidia Schapira, MD. Published online November 17, 2019. <https://aopodcast.libsyn.com/the-cattle-dont-care>
2. “Advocacy, Patient Education, and Outreach for Breast Cancer Research” with Dr Susan Love, Dr. Charu Aggarwal, and Dr. Jack West. Beyond the Journal Podcast, February 22, 2021 https://beaconmedic.com/drs-susan-love-and-stephanie-graff-on-advocacy-patient-education-and-outreach-for-breast-cancer-research-btj-009/btj-009_susan_love_stephanie_graff_thumb/
3. “Overcoming Uncertainty and Embracing Growth.” Oncology Overdrive Podcast on Healio with Dr. Shikha Jain, June 15, 2021. <https://www.healio.com/news/hematology-oncology/resources/oncology-overdrive/episode-36>
4. “Advances in Breast Cancer” Caris Molecular Minute Podcast with Dr. Chadi Nabhan, October 2021 <https://soundcloud.com/user-171589389/interview-with-dr-stephanie-graff-advances-in-breast-cancer>
5. “Breast Cancer Research” Brown Medicine Moving the Needle Podcast, November 18, 2021 <https://brownmed.org/news/brown-medicine-moving-the-needle-podcast-breast-cancer-research-with-dr-graff-ep-2/>

6. “Breast Cancer: From Diagnosis to Treatment”, MEDTECH Live Panel on Clubhouse with Amit Goldman, Dr. Yan Leyfman, Chirag Shah, and Dr. Margaret Gatti-Mays, December 2021
7. “GRASping the Importance of Patient Advocacy.” Oncology Overdrive Podcast on Healio with Dr. Shikha Jain, December 14, 2021, <https://www.healio.com/news/hematology-oncology/resources/oncology-overdrive/episode-45>
8. “Metastatic Triple Negative Breast Cancer,” with Dr. Laura Salama and Dr. Charles Milrod, Tumor Board Tuesday. Live Tweetchat with Integrity Continuing Education. Full transcript available at https://twitter.com/TumorBoardTues/status/1588712182514323458?s=20&t=iG-2wdQZ0_nRiH0UiGipaQ, November 8, 2022
9. “People Like Us” Journal of Clinical Oncology Cancer Stories: The Art of Oncology Podcast Series with Lidia Schapira, MD available at <https://aoopodcast.libsyn.com/people-like-us-what-it-means-to-be-an-outsider-in-oncology>, published online November 8, 2022
10. “Understanding Modern Medical Centers: Beyond Simone—Intersectional Maxims for a New Era” Journal of Clinical Oncology Podcast Series with Shannon N. Westin, MD, available at <https://jcopodcast.libsyn.com/intersectional-maxims-for-a-new-era-in-modern-medicine>. Published online December 9, 2022
11. “SABCS 2022: The Year of the Updates” Stephanie Graff, MD, Manali Bhawe, MD, Aditya Bardia, MD, MPH; OBR Oncology, published online Jan 10, 2023 at <https://www.obroncology.com/leading-thoughts/sabcs-2022-the-year-of-updates>
12. Outstanding Questions About Oral SERDs and Capivasertib Stephanie Graff, MD, Manali Bhawe, MD, Aditya Bardia, MD, MPH; OBR Oncology, published online Jan 26, 2023 at <https://www.obroncology.com/leading-thoughts/outstanding-questions-about-oral-serds-and-capivasertib>
13. “Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff MD FACP” Oncology Times Podcast with Sarah LaCorte, published online April 13, 2023 at <https://journals.lww.com/oncology-times/pages/collectiondetails.aspx?TopicalCollectionId=64>
14. “The Bottom Line on What Elacestrant’s Approval Means for Metastatic Breast Cancer Care” Stephanie Graff, MD, Manali Bhawe, MD, Aditya Bardia, MD, MPH; OBR Oncology posted Apr 13, 2023 at <https://www.obroncology.com/leading-thoughts/the-bottom-line-on-what-elacestrants-approval-means-for-metastatic-breast-cancer-care>
15. “More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists” Stephanie Graff, MD, and Robert A. Figlin, MD, FACP, OBR Oncology posted online Jul 18, 2023 at <https://www.obroncology.com/video/more-cage-rattling-less-talking-susan-loves-lessons-for-oncologists>
16. “Advanced and Metastatic Breast Cancer: Health Disparities and Underrepresentation of Black Women in Clinical Trials” Medscape InDiscussion: Advanced and Metastatic Breast Cancer Podcast, Episode 5. Published on 8 Aug 2023 at: <https://www.medscape.com/viewarticle/982650>
17. “Hormone Receptor Positive Breast Cancer: Year In Review” with Dr. Erica Mayer, Dr. Neil Love, Research to Practice. Published Online January 31, 2024. Available at <https://www.researchtopractice.com/YiR2023/HRPosBC/Video/1?playlistIndex>
18. “A “Tiebreaker” for Adjuvant CDK4/6 Inhibitors in Early Breast Cancer?” Dr. Erin Francis Cobain, Dr. Manali Bhawe; OBR Oncology. Published Online May 8, 2023 at <https://www.obroncology.com/leading-thoughts/a-tiebreaker-for-adjuvant-cdk4-6-inhibitors-in-early-breast-cancer>
19. “When to Treat Non-TNBC Like It’s TNBC? “Trust Your Gut” with Dr. Erin Francis

Cobain, Dr. Manali Bhavé; OBR Oncology. Published Online March 22, 2024 at <https://www.obroncology.com/leading-thoughts/when-to-treat-non-tnbc-like-its-tnbc-trust-your-gut>

20. “The Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer” Oncology Unplugged podcast with Chandler Park MD. Published online September 4, 2024 at <https://www.onclive.com/view/park-and-graff-explore-the-evolving-role-of-cdk4-6-inhibitors-in-metastatic-breast-cancer>
21. Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes Published online September 17, 2024 at https://lrn.peerview.com/150209896_1/150209896_1_p1/specialty?CountryID=US&ProjectNumber=150209896_1&MemberID=318908406
22. Shared Decision-Making in Sequencing ADCs for HER2-Low Breast Cancer, Medscape InDiscussion podcast with Kathy Miller, MD. Published online November 21, 2024 at <https://www.medscape.com/viewarticle/1001337>
23. “Brown Paper Bags: Beware of Patients Bearing Gifts” JCO : Cancer Stories. Cancer Stories: The Art of Oncology with American Society of Clinical Oncology (ASCO) Podcast Published online 12 Sept 2025, <https://aopodcast.libsyn.com/brown-paper-bags-beware-of-patients-bearing-gifts>

COMMUNITY & PATIENT FACING

1. “Frankly Speaking About Cancer: Take Control of Side Effects with Medicine, Mind & Body,” Expert Panel Discussion, Gilda’s Club Kansas City, Kansas City, Missouri, January 23, 2012
2. “Intersection of the American Cancer Society and Clinical Oncology Practice” 2018 American Cancer Society National Volunteer and Staff Leadership Summit, Dallas TX, February 8, 2018 (**Keynote Address**)
3. “Liver & Lung Metastases”, Living Beyond Breast Cancer 2019 Thriving Together Metastatic Conference, Philadelphia, PA, April 7, 2019.
4. “Breast Cancer Case Rotations,” ASCO Advantage and Cancer.Net “Cancer Basics for People with Cancer, Survivors, and the Public,” Alexandria VA, November 2019.
5. “Cancer Basics: Testing, Staging, and Grading” ASCO Advantage and Cancer.Net “Cancer Basics for People with Cancer, Survivors, and the Public,” Alexandria VA, November 2019.
6. “Candid Conversations: Mets, Sex, and Side Effects,” Panelist, San Antonio Breast Cancer Symposium Satellite Symposium, San Antonio TX, December 2019,
7. “Treatment of Hormone Receptor Positive Metastatic Breast Cancer,” Living Beyond Breast Cancer Metastatic Breast Cancer Summit, Philadelphia, PA, June 2020 (Virtual, COVID19)
8. “Male Breast Cancer & Aromatase Inhibitors, Male Breast Cancer Coalition Summit, Kansas City, MO, May 2020 (Virtual, COVID19),
9. “Searching for Unicorns: Exceptional Survivors and Responders”, Our MBC Life Podcast, March 1, 2021. <https://www.ourmbclife.org/episodes/searchingforunicorns>
10. “The Breast Cancer and COVID-19 Conundrum” Webinar, Dr. Susan Love Foundation for Breast Cancer Research, Encino, CA (Virtual), April 2021
11. “MonarchE & Male Breast Cancer,” Male Breast Cancer Coalition Summit, August 2021 (Virtual, COVID19)
1. “Changing Standards in the Treatment of Breast Cancer” Passport to Survivorship, Gloria Gemma Breast Cancer Research Foundation, Pawtucket, RI, August 2021 (Virtual, COVID19) “World Breast Cancer Research Day”, Live Panel,

- Instagram Live with Sheetal Sheth, August 2021
2. “Med-IQ: Breast Cancer Screening & Navigating the Diagnosis”, Live Panel, Instagram Live with TomikaTalks, October 2021
 12. “Frequently Asked Questions Answered” and “Questions Cancer Doctors Wished Patients Asked”, EMPOWER Cancer Patients, Total Health Conferencing, October 2021 (Virtual, COVID19)
 13. “Training Thru Treatment: Fitness and Movement After a Breast Cancer Diagnosis” Webinar, Dr. Susan Love Foundation for Breast Cancer Research, April 14, 2022, West Hollywood, CA
 14. “Understanding Progression” Our MBC Life. Published Online 21 Apr 2022 at <https://www.ourmbclife.org/episodes/understanding-progression>
 15. “Life Support: Clinical Trials for MBC. How Patients with Health and Racial Disparities Can Gain Access.” In partnership with Infinite Strength at Smilow Cancer Hospital, Yale University, New Haven, CT, June 2022
 16. “Breaking Down Common Misunderstandings of Lymphedema” Webinar, Dr. Susan Love Foundation for Breast Cancer Research, June 16, 2022, West Hollywood, CA
 17. “Her2-Low and Behold” Passport to Survivorship, Gloria Gemma Breast Cancer Research Foundation, Pawtucket, RI, October 2022
 18. “The Cost of Breast Cancer” Financial Feminist Podcast with Tori Dunlap. Published October 4, 2022 at <https://herfirst100k.com/financial-feminist-show-notes/cost-of-breast-cancer>
 19. “ASCO 2022: When The Dust Settles, Will ADCs Change MBC?” Our MBC Life Podcast, published online November 2, 2022 with Hope Rugo and Stephanie L. Graff, available at <https://www.ourmbclife.org/episodes/when-the-dust-settles>
 20. “Clinical Trials in Breast Cancer” DiepCJourney Podcast with Terri Coutee, available at <https://directory.libslyn.com/episode/index/show/diepcjourney/id/25038582>, published online 11/18/2022
 21. “ASCO 2022: When The Dust Settles, Will ADCs Change MBC?” Our MBC Life Podcast, published online November 22, 2022 with Sara Hurwitz, Kevin Kalinsky, and Stephanie L. Graff, available at <https://www.ourmbclife.org/episodes/when-the-dust-settles-part-two>
 22. “Advancing Research in Rhode Island and the TP53 Story,” Providence Making Strides Against Breast Cancer Walk, New England American Cancer Society, Providence RI, October 22, 2022
 23. “SABCS 2022 Key Take-Aways” Breastcancer.org Research Podcast. Recorded December 8, 2022. Published online December 13, 2022 at <https://www.breastcancer.org/podcast/sabcs-2022-key-take-aways>
 24. “Breast Cancer, Patient Advocacy and More.” Get Real Health with Dr. Chana Davis. Recorded February 9, 2023, available online at <https://podcasts.apple.com/ca/podcast/get-real-health-with-dr-chana-davis/>
 25. “Recent Advances, Controversies, and Emerging Trends in MBC” Our MBC Life Podcast, published online May 31, 2023, available at <https://www.ourmbclife.org/episodes/rtac-current-trends-and-controversies>
 26. ASCO23 Wrap-Up. Breastcancer.Org Research Podcast published online June 7, 2023, available at <https://www.breastcancer.org/podcast/asco-2023-takeaways>
 27. “NATALEE, SONIA, X-7/7—Findings from ASCO23” Oncology Brothers and Targeted Oncology, Published online 15 June 2023 at <https://oncbrothers.com/breast-asco2023/>
 28. “OMBCL Shorts: Dr. Stephanie Graff and Her Steps for Those Newly Diagnosed with

- MBC.” Our MBC Life, published online 17 June 2023 at <https://www.ourmbclife.org/episodes/ombcl-shorts-dr-graff>
29. “The Medical Minute - Ep. #74 - ASCO Direct™: A Patient Perspective” ft. Dr. Stephanie Graff, Cincinnati Cancer Advisors YouTube Channel, Virtual/Cincinnati OH, published online July 19, 2023 at https://www.youtube.com/watch?v=9a_lyKlnilg
 30. “Chemotherapy Induced Peripheral Neuropathy” 2023 Bret Miller 1T Male Breast Cancer Happens Virtual Conference, November 2, 2023
 31. “SABCS Key Highlights 2023”, Living Beyond Breast Cancer Virtual Webinar, December 12, 2023
 32. “Metastatic Breast Cancer; Male Breast Cancer; Tumor & Immune Microenvironment,” GRASP Poster Walkthroughs, San Antonio Breast Cancer Symposium, Virtual, December 15, 2023
 33. “On the Ground at SABCS: Clinical Meaningfulness Poster Walk-Thru” Triple Negative Breast Cancer Foundation. Published online December 14, 2023 at <https://tnbcfoundation.org/about-us/our-events/your-guide-to-the-2023-san-antonio-breast-cancer-symposium-2/on-the-ground-at-sabcs-2>
 34. “All Cancers; Brain Metastasis; Leptomeningeal Disease; HER3 Antibody-Drug Conjugates; Clinical Trials” GRASP Poster Walkthroughs, American Society of Clinical Oncology, Virtual, June 13, 2024
 35. “Why We Walk” Relay for Life, Brown University American Cancer Society Student Chapter Relay for Life Event, April 18, 2025
 36. “Advancing Cancer Research in Rhode Island: Cures & Care” Brown University Health Community Health Ambassador Lecture Series, May 27, 2025
 37. “Episode 13: Unlocking the Potential of Immunotherapy in TNBC” Susan G. Komen Breast Cancer Break Throughs Series, July 22, 2025 available online at <https://www.komen.org/about-komen/our-impact/breast-cancer/breast-cancer-breakthroughs-series/>
 38. “Breast Cancer in Rhode Island” Brown University Health Community Health Ambassador Lecture Series, October 14, 2025
 39. “Hot Topics” 28th Annual Alamo Breast Cancer Foundation Alamo Advocate Program, San Antonio Breast Cancer Symposium, San Antonio TX, December 2025

CLINICAL RESEARCH EXPERIENCE

Includes ongoing clinical trials and/or negative trials not otherwise published; published studies have been removed

1. A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum-based chemotherapy. Sub-Investigator
2. 10043P: A Prospective Study of Clinical Outcomes for the Pathwork “Tissue of Origin Test.” Sub-Investigator
3. A Phase 2 Randomized Open-label Study of MED 551 in Adults with Relapsed or Refractory DLBCL. (NCT01453205; MedImmune LLC) Sub-Investigator
4. A randomized multicenter Phase II trial to evaluate the safety and immunogenicity of two doses of vaccination with Folate Receptor Alpha peptides with GM-CSF with Triple Negative breast cancer (BRE-273; TapImmune) Principal Investigator
ClinicalTrials.gov updated to reflect “Futility analysis did not support continuation analysis of this trial” 15 DEC 2022 <https://classic.clinicaltrials.gov/ct2/show/NCT02978222>

5. A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer (NCT03371017, BRE 304, Impassion132; Genentech) Principal Investigator
6. A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations (NCT02795156, PRO 10, Sarah Cannon Research Institute), Principal Investigator
7. An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS; NCT03786094 BRE 346; Polyphor Ltd), Principal Investigator
Negative press release issued by sponsor: <https://spexisbio.com/news/corporate-news-details/?newsid=2129439>
8. A Phase III Randomized Double-Blind Placebo Controlled Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib compared with Letrozole combined with Palbociclib in patients with estrogen receptor positive, Her2 negative locally advanced or metastatic breast cancer (NCT04546009, BRE352, persevERA; Hoffman-Roche), Principal Investigator
9. A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (NCT04251533, BRE 353, Novartis), Principal Investigator
10. A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-04, NCT04539938, BRE 358, SeaGen), Principal Investigator
11. DFCI Elevate: Improving Outcomes for Older Patients with Breast Cancer -a Longitudinal Cohort and Patient Engagement Study (NCT03818087; Site Sub-Investigator)
12. DFCI VICTORY: A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients with Early-Stage OR Newly Diagnosed Metastatic Disease: VICTORY (Sub-Investigator)
13. Improving Breast Cancer Patient Distress Scores with Incorporation of Online Therapeutic Platform, BrUOG 402 (Sub-Investigator)
Study terminated by sponsor
14. A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (GS592-6173, Gilead, ASCENT-04), Principal Investigator
15. STOP CIPN: Randomized Trial of Limb CryocompreSsion versus ConTinuOUS COMPreSSion versus Low Cyclic Compression for the Prevention of TaxaneInduCed PerIPheral Neuropathy (SWOG-S2205, NCT05642611), **SWOG Community Chair**, Principal Investigator
16. A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-

- 1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast02, AstraZeneca), Principal Investigator
17. Real-world economic outcomes and impact on work productivity associated with treatment induced adverse symptomatic events in patients with hormone receptor positive metastatic breast cancer treated with CDK4/6 inhibitors. (BrUOG 417), Principal Investigator
 18. Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (SWOG S2013, NCT04871542), Sub-Investigator
 19. A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSEssment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib (Alliance, NCT05812807) Sub-Investigator
 20. A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (EMBER-4, J2J-MC-JZLH; Eli Lilly) Principal Investigator
 21. A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03; Astra-Zeneca, SWOG Clinical Trial Partnerships); Principal Investigator
 22. A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Durvalumab compared with Pembrolizumab in combination with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel/ Gemcitabine+Carboplatin) in Patients with PDL1 positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05), **Global Steering Committee and US Investigator for the FDA submission**
 23. Phase 1, 2-part, Multicenter, First-in-human Dose-escalation and Dose-expansion Study of DS-1103a Combination Therapy in Subjects with Advanced Solid Tumors (DS1103-074, COAST; Daiichi Sankyo, NCT05765851), Principal Investigator
 24. A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in broader and closer to real-World patient populations in stage II and stage III Early breast cancer (WIDER, Novartis, NCT05827081) **Co-Chair, Global Steering Committee**
 25. S2212, Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer, A Randomized Phase III Study (SCARLET, SWOG S2212, NCT05929768), Sub-Investigator
 26. A Phase III, Randomized, Open-Label Study Evaluating Efficacy And Safety Of Giredestrant Compared With Fulvestrant, Both Combined With A Cdk4/6 Inhibitor, In Patients With Estrogen Receptor-Positive, Her2-Negative Advanced Breast Cancer With Resistance To Prior Adjuvant Endocrine Therapy (LS-P-pionERA)
 27. AFT-EndoMAP: A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer, Sub-Investigator
 28. LS-P-POPPY: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors, Sub-Investigator
 29. LS-P-CYCAD-1: A Phase I/IIa, First-in-human, Open-label, Dose Escalation and

Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors (CYCAD-1; AstraZeneca, NCT06188520), Principal Investigator

30. LS-P-SODA: Phase 1/2, Open-Label Multicenter First In Human Study of DS3939A in subjects with Advanced Solid Tumors (Daiichi Sankyo) Sub Investigator
31. LS-P-DF1001: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications, Sub Investigator
32. LS-P-WiSH: Phase 1, First-In-Human, Open-Label Dose Escalation And Cohort Expansion Study Of KB-0742 In Patients With Relapsed Or Refractory Solid Tumors Or Non-Hodgkin Lymphoma, Sub Investigator
33. BH-P-ELEGANT (STML-ELA-0422): Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (Stemline; NCT06492616); Principal Investigator
34. EmpowHER-303 (JZP598-303): A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment, Principal Investigator, (Jazz Pharmaceuticals, JZP598-303)
35. LoTam: A randomized, phase III clinical trial of low-dose tamoxifen for selected patients with molecular low-risk early-stage breast cancer (Alliance A012301, Site Sub-Investigator)

TEACHING, ADVISING and MENTORING ROLES

High School Students

1. Dahlia Pahlavi, 2022-2023
Barrington High School, Barrington RI
Project: Language Bias in Medicine
**Early Admission to Brown University*
2. Gabriella De La Cruz, 2025
St. Mary Academy – Bay View High School, Providence RI
Clinical Mentor, Future Gen Cancer Scholars Program at Brown University

Undergraduate Students

1. Emma Safran, BA, 2022-2023
Project: A multicenter retrospective study on the prognostic impact of pregnancy in women with history of BRCA mutated breast cancer. Published: Lambertini M, Blondeaux E, Agostinetto E, et al. BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2024 Jan 2;331(1):49-59.
**Accepted to University of New England School of Medicine*

Graduate Students

1. Roxanne Wood, BA, CCRC, MPH Candidate

Brown University School of Public Health

Project: Implementing Collection of Sexual Orientation and Gender Identity (SOGI)

Medical Students

1. Sabrina Arezo, MS, 2022-2025
Warren Alpert School of Medicine, Brown University
Mentor, Doctoring Mentor Program 2022-2023
Mentor, Advanced Clinical Mentorship in Internal Medicine, 2023-2024
Project: Implementing Collection of Sexual Orientation and Gender Identity (SOGI)
Project: Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. Hsu E, Arezo SM, Graff SL. *Accepted for publication, 21 Aug 2024, Curr Treat Options Oncol.*
**Accepted to Internal Medicine Residency at Duke University*
2. Emilija Sagaityte, MS, 2022- 2023
Warren Alpert School of Medicine, Brown University
Project: FTO Inhibition in Breast Cancer Brain Metastases; accepted “The Role of RNA Epitranscriptomics and the RNA Fat Mass and Obesity-Associated Demethylase in Triple Negative Breast. *Advances in Breast Cancer Research, 2023 (12)*
3. Parker Haddock, 2024 -
Warren Alpert School of Medicine, Brown University
Mentor, AMS Summer 2024 Program & Scholarly Concentration
*Project: HOLIDAAY Care Study: **H**oliday **O**n-call **I**nfusion, **D**elays, **A**dmissions, **A**ccess and **Q**ualit**Y** **C**are Study; *Accepted for presentation in the Medical Student & Abstract Forum, 2025 ASCO Annual Meeting**
4. Celeste K. Nsubayi, 2024-
Warren Alpert School of Medicine, Brown University
Project: Real-world discordance between patients with HR+/HER2- mBC and their physicians for reporting symptoms and side effects across EU5 and the US. European Society of Medical Oncology Breast Cancer 2025; Accepted for Poster Presentation
5. Alexa Streckler, 2024-
Warren Alpert School of Medicine, Brown University
Project: Adams M, Lock YJ, Steckler A, Kumar S, Dizon S, Duffy CM, Fenton MA, Sauerbrun-Cutler MT, Graff SL. Pregnancy and Parenthood after Breast Cancer. Accepted 17 JUN 2025, Current Breast Cancer Reports

Residents

1. Anna D. Louie, MD, 2021-
Department of Surgery Research Fellow, Brown University; Surgery Resident, Duke University
Project: Mutational landscape and immune infiltration of breast cancer metastases to gynecologic and other organs. Accepted as a Spotlight Poster Presentation to the 2021 San Antonio Breast Cancer Symposium, Wednesday December 6, 2021.
Louie AD, Bansal R, Wu S, Capelletti M, Magee D, Korn WM, Kaklamani V, Tan AR, Chalasani P, El-Deiry WS, Dizon DS, Graff SL Genomic characterization of breast cancer by metastatic site and impact of variable co-expression of genomic mutations including CDH1 and PIK3CA on survival. *Manuscript in submission.*

2. Gerneiva Parkinson, MD, 2021-2024
Internal Medicine Resident
Brown University-Warren Alpert Medical School
Project: Investigating HBOC Germline Mutations in Trinidad and Tobago Breast Cancer Patients: Integrating Research into Existing Clinical Infrastructure, ongoing
Project: Genomic predictors of response in BRCA-mutated Breast Cancer, *Accepted—Mini Oral Presentation*, European Society of Medical Oncology Congress 2024;
Parkinson G, et al. Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing,
**Matched Hematology/Oncology Fellowship Stanford University, Palo Alto, CA*
3. Jessica Gonzalez, MD 2022-2023
Internal Medicine Resident, Arts & Medicine Track Brown University-Warren Alpert Medical School
Projects: Radiation Induced Sarcoma Presenting as an Anterior Mediastinal Mass with Pericardial Invasion, Presented at Brown Research Day
4. Stephanie Haddad, MD, 2022- 2024
Internal Medicine Resident
Brown University/Kent Hospital Internal Medicine Residency Program, Warwick, RI
Project: Haddad SA, Dizon DS, Graff SL. Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm. *Chin Clin Oncol.* 2023 Aug;12(4):42. doi: 10.21037/cco-23-22. Epub 2023 Aug 10. PMID: 37574571.
Project: Safety and Efficacy of KEYNOTE-522 in combination with anti-retroviral therapy in a patient with HIV and triple-negative breast cancer. Haddad, SA, Graff SL, Wang Y, Taneja C, Leonard K, Fenton MA Clinical Case Studies, 2023 San Antonio Breast Cancer Symposium 2023 Poster Presentation,
**Matched Hematology/Oncology Fellowship at University of Texas-San Antonio, San Antonio, TX*
5. Jane Lock, MD PhD, 2024 – 2025
Internal Medicine Resident
Brown University-Warren Alpert Medical School
Projects: Adams M, Lock YJ, Steckler A, Kumar S, Dizon S, Duffy CM, Fenton MA, Sauerbrun-Cutler MT, Graff SL. Pregnancy and Parenthood after Breast Cancer. *Curr Breast Cancer Rep* 17, 27 (2025). <https://doi-org.revproxy.brown.edu/10.1007/s12609-025-00594-1>
Second Site Clinic Mentor, January-July 2025
6. MacKenzie Adams, MD, 2024—
Internal Medicine Resident
Brown University-Warren Alpert Medical School
Project: Adams M, Lock YJ, Steckler A, Kumar S, Dizon S, Duffy CM, Fenton MA, Sauerbrun-Cutler MT, Graff SL. Pregnancy and Parenthood after Breast Cancer. *Curr Breast Cancer Rep* 17, 27 (2025). <https://doi-org.revproxy.brown.edu/10.1007/s12609-025-00594-1>

1. Rani Chudasama, MD 2021-2023
Division of Hematology/Oncology
Brown University
Project: Mutational landscape and immune infiltration of breast cancer metastases to gynecologic and other organs. *Accepted as a Spotlight Poster Presentation to the 2021 San Antonio Breast Cancer Symposium, Wednesday December 6, 2021.*
Project: Mutational landscape of Her2 low metastatic breast cancer, *Abstract accepted to special poster session, San Antonio Breast Cancer Symposium, 2022; Manuscript in Submission*
**Accepted position as Assistant Professor of Medicine, Hematology/Oncology Division, Duke University*
2. Laura Salama, MD 2021- 2023
Division of Hematology/Oncology
Brown University
Project: Evaluating Use of Twitter Spaces for Breast/Gynecology Oncology Journal Club
**Accepted position Dartmouth Medical Center, Hematology/Oncology*
3. Brianna Bakow, MD 2022-present
Division of Hematology/Oncology
Brown University
Project: “The Prevalence of Sick Cell Phenotype and its Association with Clinical Outcomes in Patients with Solid Malignancies.” *Poster Presentation, American Society of Clinical Oncology Annual Meeting 2024*
4. Dharmini Manogna, MD 2023- present
Tulane University
Project: “Genomic and Tumor Microenvironment Dynamics of Brain Metastases in Breast Cancer” *Mini-Oral Presentation, American Society of Clinical Oncology Annual Meeting 2024*
5. Ahmed Khalil, MD 2023- 2024
Division of Hematology/Oncology
University of Maryland
Project: “Optimizing the Oncology Ecosystem: Addressing Barriers Between Community and Academic Oncologists.” *Abstract, American Society of Clinical Oncology Annual Meeting 2024*
6. Ghazal Kango, MD 2023- 2024
Division of Hematology/Oncology
University of Maryland
Project: “Optimizing the Oncology Ecosystem: Addressing Barriers Between Community and Academic Oncologists.” *Abstract, American Society of Clinical Oncology Annual Meeting 2024*
7. Hetal Mistry, MD 2024-present
Division of Hematology/Oncology
Brown University
Project: “Analyzing Neurologic Outcomes in Breast Cancer Patients with Central Nervous System Disease”

**Accepted position Assistant Professor of Medicine, University of Pittsburgh Medical Center*

8. Marko Velimirovic, MD, MMSc
Hematology/Oncology Division
Cleveland Clinic Taussig Cancer Institute
Project: The role of APOBEC3 mutational signatures in tumorigenesis and therapeutic response in metastatic breast cancer
Project: Genomic Landscape of De Novo Locally Advanced or Metastatic TNBC vs. Locally Advanced or Metastatic TNBC That Emerges Following Treatment of Primary Early or Metastatic ER-Positive, HER2-Negative Breast Cancer

Assistant Professors

1. Maria Constantinou, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Brown University
Project: Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors, SWOG S2013
2. Sabrina Witherby, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Brown University
Project: Evaluating Use of Twitter Spaces for Breast/Gynecology Oncology Journal Club (2021-2024)
3. Sheldon Holder, MD, PhD
Assistant Professor of Pathology and Laboratory Medicine
Brown University
Project: Understanding PIM1 expression in isolation and against CDK4/6 or mTOR inhibition in breast and kidney cancers, presented abstracts at ESMO Congress 2023, AACR Annual Meeting 2024, manuscript in submission
4. Emily Hsu, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Brown University
Project: In Development, Optimizing CDK4/6 Inhibitors in Hormone-Receptor Positive Metastatic Breast Cancer, as part of Robert A. Winn Career Development Award
Project: Updates in Systemic Treatment of Hormone Receptor-positive Early-Stage Breast Cancer, Current Treatment Options in Oncology, (Invited Review)

Associate Professors

1. Mary Anne Fenton, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Brown University
Project: Fenton MA, Tarantino P, Graff SL. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Curr. Oncol. 2023, 30(12), 10211-10223; <https://doi.org/10.3390/curroncol30120743>

Institutional Advising/Mentoring

1. Cancer Prevention and Survivorship Elective, Faculty Mentor—Breast Cancer Clinic, Warren Alpert School of Medicine Internal Medicine Residency, 2024 -
2. Matilda Society, Brown University Health Division of Hematology and Oncology, Co-Founder, July 2024 - present
Institutional committee with mission to advance the careers of women in the division through mentorship, sponsorship, education, and advocacy, creating opportunities for equity in advancement, leadership, valuation, and research.
 - a. Led quarterly retreats to evaluate opportunities, share best practices, and advance career goals for members
 - b. Supported creation of divisional role for academic promotion support
 - c. Developed and led workshop supporting enhanced billing and coding skills for women in division as means to enhance equity in valuation
 - d. Coordinated grateful patient training with Health System Chief Development Office
 - e. Pursued opportunities to nominate women for awards, 3 total awards recipients to date.
 - f. Initiated updated web content with inclusive faculty content
3. Future Gen Cancer Scholars Program, Brown University Health, Program Mentor, Summer 2025

National Advising/Mentoring

1. American Society of Clinical Oncology Annual Meeting Career Mentoring
 - a. Ragisha Gopalakrishnan, MD—2019
Hematology/Medical Oncology Fellow
Vanderbilt University, Nashville TN
 - b. Chrystal Landry, MD—2019
Breast Oncologist
Northwell Health, Lake Success, NY
 - c. Maria Garcia-Jimenez, MD/MHS—2021
Clinical Instructor of Medicine
Division of Hematology/Oncology, UCLA David Geffen School of Medicine
 - d. Rahul & Rohit Gosain—2022
“Oncology Brothers”
 - e. Prarthna Bhardwaj, MD, FACP—2022
Hematology/Medical Oncology Fellow
UMass Chan-Baystate, Springfield, MA
 - f. Shafia Rahman, MD—2022
Hematology/Medical Oncology Fellow
The Ohio State University James Cancer Center, Columbus OH
 - g. Mazie Tsang, MD, MS—2023
Assistant Professor, Hematology/Medical Oncology/Palliative Care
Mayo Clinic School of Graduate Medical Education, Phoenix, AZ
 - h. Shipra Gandhi, MD—2023
Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center, Buffalo, NY
 - i. Arya Mariam Roy, MD—2023
Hematology/Medical Oncology Fellow

- Roswell Park Comprehensive Cancer Center, Buffalo, NY
- j. Esther Chong, MD—2024
Hematology/Medical Oncology Fellow
Loma Linda University Health, Loma Linda, CA
 2. American Society of Clinical Oncology Virtual Mentoring Program: *ASCO's Virtual Mentoring Program pairs members with a mentor outside of their institution through virtual technology to address unmet career development needs of trainees, residents, and early-to-mid-career oncologists over a 1-year mentor commitment.*
 - a. Jasmine Kamboj, MD—2024-2025
Mayo Clinic, Rochester MN
 - b. Michael Assefa, MD—2025-2026
Northside Hospital, Atlanta GA
 3. American Society of Clinical Oncology JCO Journal Editorial Fellowship Art of Oncology Editorial Fellow: *The JCO Journals Editorial Fellowship is designed to introduce oncology fellows to the peer review, editing, and publishing of medical research manuscripts in journals. Fellows get a direct and immersive experience into how a manuscript is handled, from submission to final decision.*
 - a. Laura Vater, MD MPH—2025-2026
Indiana University
Simon Comprehensive Cancer Center
Indiana University School of Medicine
August 2025, April 2026
 4. Career Development Lectures & Workshops
 - a. "Negotiation Skills: Getting What You Need" Women's Networking Center, American Society of Clinical Oncology Annual Meeting 2018, Chicago, IL, June 2, 2018
 - b. "Presentation Skills: How to Give a Good Talk," Trainee & Early Career Oncologist Lounge, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 2, 2019
 - c. "How to Negotiate Successfully for What Matters," Women's Networking Center, American Society of Clinical Oncology Annual Meeting 2019, Chicago, IL, June 1, 2019
 - d. "Building Your Brand." Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
 - e. "A Social Media Toolkit to Enhance Your Career," Panelist, LEAD: Leadership Empowerment and Development, Enriching Experiences for Women in Hematology and Oncology. Santa Monica CA, October 2019
 - f. "Landing Your First Job" Trainee & Early Career Oncologist Lounge, American Society of Clinical Oncology Annual Meeting 2020, Chicago, IL, June 2020 (Cancelled, COVID-19)
 - g. "A Day In The Life of an Oncologist", Oncology Summer Internship Program, American Society of Clinical Oncology webinar, Alexandria, VA (Virtual), June 2021
 - h. "Careers in Breast Cancer" San Antonio Breast Cancer Symposium 2023 Satellite Meeting, with Caris Precision Oncology Alliance, December 2021

- i. “Career Transitions In Oncology”, ASCO Women In Oncology Fireside Chat, panelist, Virtual, Arlington VA, December 2021
 - j. “Beyond Imposter: Celebrating Your Confidence and Success at Work”, Women’s Networking Center, American Society of Clinical Oncology Annual Meeting, Chicago IL, June 6, 2022
 - k. National Fellows Forum—Breast Cancer, San Antonio Breast Cancer Symposium with OncLive, **Chair**, August 2023-December 2023: *Developed curriculum, served as mentor to 6 selected fellows; reviewed submitted abstracts; provided feedback on research concepts and presentations; networking for 30 fellows to facilitate career development; presented to forum on career development.*
 - l. Mentorship & Sponsorship Roundtable Discussion”, Women’s Networking Center, American Society of Clinical Oncology Annual Meeting 2023, Chicago IL, June 5, 2023 “Pivoting to New Paths – Charting a New Way Forward,” ASCO Professional Development Series for Women in Oncology, November 14, 2023, Virtual
 - m. Women In Oncology Panel, Miami Breast Cancer Conference, Panelist & Co-**Chair**, Developed curriculum January – March 2024; Event and lectures March 7, 2024
 - n. National Fellows Forum—Breast Cancer, San Antonio Breast Cancer Symposium with OncLive, **Chair**, April 2024 - December 2024: *Developed curriculum, served as mentor to selected fellows; reviewed submitted abstracts; provided feedback on research concepts and presentations; networking for 19 fellows to facilitate career development; presented to forum on engaging professional societies.*
 - o. “Management Styles: Getting the Best Out of Your Team” Women’s Networking Center, American Society of Clinical Oncology Annual Meeting 2024, Chicago, IL, June 2, 2024
 - p. Build It & They Will Come: A Leader’s Guide to Building Breast Programs Leadership Program, National Consortium of Breast Centers Annual Interdisciplinary Breast Cancer Conference Co-Chair, March 2025
 - q. “Navigating Career Transition”, Women’s Networking Center Roundtable, 2025 American Society of Clinical Oncology Annual Meeting, Chicago IL, May 30, 2025
 - r. “Influential Leadership”, Brown University Hematology-Oncology Fellows Noon Conference, June 5, 2025, Providence RI
 - s. National Fellows Forum—Breast Cancer, San Antonio Breast Cancer Symposium with OncLive, Faculty, August 2025-December 2025
5. GRASP Scientist < > Advocate Poster Talk Program
GRASP (Guiding Researchers and Advocates to Scientific Partnerships) is a non-profit that works connecting patient advocates and conference attendees with senior advocates, clinicians and scientists to discuss poster presentations and critical appraisal of breaking science
- a. San Antonio Breast Cancer Symposium, 2019
 - b. American Society of Clinical Oncology, 2020
 - c. American Society of Clinical Oncology, 2022
 - d. American Society of Clinical Oncology, 2023
 - e. San Antonio Breast Cancer Symposium, 2023
 - f. American Society of Clinical Oncology, 2024
 - g. San Antonio Breast Cancer Symposium, 2024
 - h. American Society of Clinical Oncology, 2025

International Advising/Mentoring

1. American Society of Clinical Oncology International Development and Education Award (IDEA) Program Mentor
 - a. Dr. Mary Antonette Ong, 2024
Iloilo City, Philippines
 - b. Dr. Dana Narvaez, 2025
Ciudad de Buenos Aires, Argentina
2. Odette Cancer Program, Sunnybrook Health Services Centre, Toronto, Ontario Canada
 - a. Visiting Professor Mentorship Sessions, November 2024
 - i. Dr. Dan Moldoveanu, Breast Surgical Oncologist
 - ii. Dr. Italo Fernandes, Breast Medical Oncologist